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ABSTRACT 
MOLECULAR BASES OF INHERITED BONE MARROW FAILURES: 
SHWACHMAN-DIAMOND SYNDROME AND DIAMOND BLACKFAN ANEMIA
Adrianna Lee Henson 
August 15, 2012 
 Inherited Bone Marrow Failure syndromes (IBMFS) are a heterogeneous 
class of diseases that converge on very few subjects. They are unified by a block 
in maturation of one or multiple blood lineages, are genetically inherited, and 
have an increased incidence of cancers and myelodisplastic syndromes.  Several 
IBMFSs have been linked to defects in ribosome biogenesis. Diamond Blackfan 
anemia (DBA) which presents with a macrocytic anemia has 10 known affected 
genes all of which encode structural proteins  of the large or small ribosomal 
subunit. In contrast, there is only a single gene known to be involved in the 
pathogenesis of Shwachman Diamond Syndrome (SDS) which usually presents 
as exocrine pancreatic insufficiency along with neutropenia.  
 Investigation of DBA pathogenesis lead to the knowledge that deficiency 
of certain ribosomal proteins leads to a specific defect in ribosomal pre-RNA 
processing. In this work, we have identified a new DBA gene, RPL31, by isolating 
mononuclear cells from the patient’s blood and subsequently harvesting total 
RNA used for Northern blotting to identify delays in pre-rRNA processing in both 
this patient as well as those found in a patient with other large subunit DBA 
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mutations.  Additionally, we have created a human cell model of SDS that has 
allowed us to explore changes in respiration originally shown in yeast models.  To 
this end, we have identified increases in reactive oxygen species,  changes in 
oxygen consumption, mitochondrial membrane potential, and cell cycle delay, all 
linked to depletion of SBDS protein.  
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CHAPTER I
RIBOSOME DYSFUNCTION AND MARROW FAILURE 
The Mammalian Ribosome: Structure and Function
 The ribosome is responsible for translating the coded messages of mRNA 
and catalyzing peptide bond formation between individual amino acids to 
generate proteins. The ribosome thus functions as an enzyme, or ribozyme due 
to its catalytic activity being embodied in its RNA rather than protein components 
(Cech, 2000).  Recent work on the crystal structure for the mammalian ribosome 
has provided insight into the spatial arrangement of proteins and RNAs forming 
this remarkable complex (Ben-Shem et al., 2010). The mammalian ribosome is 
composed of four distinct ribosomal RNAs (rRNAs), and 80 ribosomal proteins 
(RPs).  Ribosomal proteins are named using the nomenclature of RPL for 
proteins of the large ribosomal subunit and RPS for the small ribosomal subunit. 
In addition to its structural components, ribosome synthesis requires more than 
200 essential non-ribosomal trans-acting factors including both accessory 
proteins and small nucleolar ribonucleoprotein particles (snoRNPs) (Jackson et 
al., 2010).   Large structures like ribosomes are often spoken of in terms of 
Svedberg units based on their rate of migration in a centrifugal field, such as 
40S, for the small ribosomal subunit. During protein synthesis, the 40S subunit 
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binds to mRNA and scans down its length until it encounters an AUG start codon.  
This complex, known as the 40S initiation complex, requires a number of 
initiation factors and GTP to bind and once formed awaits the joining of a 60S 
subunit to form the 80S initiation complex.  Formation of the 80S initiation 
complex requires energy, the recruitment of additional initiation factors, and the 
release of others.  Once formed, the 80S initiation complex is ready to enter the 
elongation phase of protein synthesis as the ribosome translates down the 
mRNA.  
 The production of ribosomal subunits is exquisitely regulated such that 
equal amounts of 40S and 60S subunits are produced in response to a number 
of physiologic, developmental, and environmental cues in amounts that are 
proportional to the needs of the cell (reviewed in (Warner, 1990)).  This process 
is highly complex and occurs in a specialized organelle called the nucleolus, 
which is found within the nucleus. Ribosome synthesis involves the coordinate 
activities of RNA polymerase I and III producing RNA components of the 
ribosome and RNA polymerase II producing transcripts for ribosomal proteins.  
Ribosomal protein transcripts are translated in the cytoplasm and proteins 
imported into the nucleus and subsequently travel to the nucleolus where the 
rRNAs are being transcribed.  Ribosome assembly occurs co-transcriptionally as 
ribosomal proteins load onto nascent RNA polymerase I transcripts in forming 
pre-ribosomal subunits.  These pre-subunits continue to mature as additional 
ribosomal proteins are incorporated, 5S rRNA produced by RNA polymerase III is 
also incorporated into maturing 60S subunits.  Ribosome biogenesis also 
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requires post transcriptional and post translational modifications of ribosomal 
RNA and protein, respectively.  Finally, additional factors are involved in subunit 
transport from the nucleus to the cytoplasm (Zemp and Kutay, 2007).  
 Pre-rRNA processing
 Three of the four mature rRNAs are synthesized from a large polycistronic 
45S pre-rRNA transcript synthesized by RNA polymerase I.  This organization 
assures the equimolar production 18S, 5.8S and 28S RNA components of the 
ribosome.  Only the 5S rRNA, transcribed by RNA polymerase III, is not found in 
this organizational unit.  In yeast, the rDNA unit includes coding regions for both 
5S rRNA and the 45S RNA.  This coding unit is repeated from 30 to 500 times in 
the genome and this spatial organization may allow the coordination of RNA 
polymerase I and III activities in producing the four rRNAs.  In mammalian cells, 
the 5S rDNA is not physically linked to the remaining rDNA repeat units.  The 
rDNA repeats are clustered at various sub-telomeric regions on different 
chromosomes.  The basis for locating 5S rDNA independently of the other rDNA 
repeat units in many higher organisms, including humans, is unknown (Ciganda 
and Williams, 2011). 
 In addition to the mature 18S rRNA of the 40S subunit and the 5.8S and 
28S rRNAs of the 60S subunit, the 45S pre-rRNA contains external flanking 
sequences (ETS: external transcribed sequences) and two internal transcribed 
sequences (ITS1 and ITS2).  Thus, to liberate the mature rRNA species the 45S 
pre-rRNA must undergo a series of endo- and exonucleolytic processing steps 
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which occur concurrently with the assembly of ribosomal proteins onto nascent 
transcripts.  Other processing events occur co-transcriptionally to the 45S pre-
rRNA including methylation and pseudouridinylation (Fromont-Racine et al., 
2003).  The current view of the numerous steps involved in the maturation of 
mammalian 45S pre-RNA are outlined in a simplified version in Fig. 1.  The vast 
majority of these processing steps occur in the nucleolus although some later 
steps in maturation occur in the cytoplasm (Flygare et al., 2007).  Limiting the 
amount of many of the factors required for ribosome synthesis have been shown 
to cause delays in maturation of pre-rRNA as evidenced by the accumulation of 
distinct pre-rRNA intermediates.  For example, when one copy of RPS19 is 
mutated in patients with an inherited bone marrow failure syndrome (IBMFS), 
Diamond Blackfan anemia (DBA), there is a delay in the maturation of the 3′ end 
of 18S rRNA which can be visualized by Northern blotting as an increase in 21S 
pre-rRNA (Flygare et al., 2007).  This strategy of employing Northern blot 
analysis to identify specific defects during the process of ribosome synthesis is 
used throughout the first part of this dissertation.  This will be discussed in more 
detail in subsequent chapters and Northern blot oligonucleotides used in this 
dissertation to identify processing defects in pre-rRNA  resulting from mutations 
in genes encoding ribosomal proteins are shown in Table 1 of Chapter 2.  
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Fig 1: Mature rRNAs are liberated from a large polycistronic transcript by a 
series of endo and exonucleolytic cleavage steps.  
The 45S pre-rRNA transcribed by RNA polymerase I is shown at the top of the 
figure. This transcript undergoes multiple exonuclease and endonuclease 
processing steps to form mature 18S, 5.8S, and 28S rRNAs.  The pathway 
shown here is the major pathway found in mononuclear cells derived from human 
blood and in the TF-1 human erythroleukemia cell line.   
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 Synthesis of Ribosomal Subunits
While pre-rRNA processing is a way of tracking different steps in ribosome 
synthesis, these processing events are only a small part of the overall process of 
ribosome synthesis that begins with nucleolar transcription by RNA polymerase I 
and ends with functional ribosomal subunits in the cytoplasm.  The “Christmas 
tree” appearance of pre-rRNA transcription was described decades ago (Miller 
and Beatty, 1969).  These nascent transcripts begin at rDNA promoters and get 
longer the further they extend from the initiation site.  The high transcription rates 
of rDNA in rapidly dividing cells give rise to numerous pre-rRNAs being 
transcribed simultaneously giving the characteristic Christmas tree appearance.  
More detailed Miller spreads of rDNA transcription units in eukaryotic cells have 
revealed that these nascent pre-rRNA transcripts begin to ball up as ribosomal 
proteins and various trans-acting factors assemble co-transcriptionally on the 
45S pre-rRNA (Miller and Beatty, 1969).  
The earliest complex in the process of ribosome synthesis that can be 
biochemically identified is the 90S pre-ribosomal particle.  This complex includes 
the small subunit processome (SSU) which gathers on the 18S rRNA domain at 
the 5′-end of the 45S pre-rRNA.  The SSU includes the U3 snoRNP which is 
involved in promoting endonucleolytic cleavages in the 5′-ETS and ITS1 and so 
plays a critical role in the maturation of the 40S ribosomal subunit (Dragon et al., 
2002).    Although numerous ribosomal proteins and factors required for the 
assembly of the 40S subunit are found in the 90S species, no large subunit 
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ribosomal proteins or 60S trans-acting factors are found in this early complex 
(Gavin et al., 2002; Grandi et al., 2002).
 After the 90S species goes through the processing steps in ITS1, the 
pre-40S subunits separate from the pre-60S subunit to begin further independent 
steps in subunit maturation.  Pre-40S subunits containing an immature 20S pre-
rRNA recruit additional proteins as maturation continues, and pre-40S subunits 
are transported out of the nucleus.  For example Tsr1 is necessary for processing 
of 20S pre-rRNA and the export of pre-40S subunits from the nucleus, even 
though it is present in the 90S complex.  Tsr1 must be added to the pre-40S 
complex after its release from the 90S complex.  Many trans-acting factors 
associated with the pre-40S subunits are released before exiting the nucleus 
(Jackson et al., 2010; Moy and Silver, 2002; Panse, 2011).  
The formation of 60S subunits is considerably more complicated than that 
of the 40S subunit and involves the maturation of three rRNA species, the 
incorporation of over 30 ribosomal proteins, and requires over 100 trans-acting 
factors.  Maturation of 60S subunits begins in the nucleolus but is eventually 
completed within the cytoplasm.  After the pre-40S and pre-60S subunits are 
formed, the two subunits undergo divergent processing steps on their way to the 
nuclear pore complex where NESs (nuclear export sequences) present on both 
pre-subunits are recognized by the export factor Xpo1, also known as Crm1 (Hurt 
et al., 1999; Moy and Silver, 1999, 2002; Stage-Zimmermann et al., 2000). The 
molecules of the pre-40S subunit that are recognized by Crm1 include Ltv1, 
Dim2, and Rio2, the only trans-acting factor with a NES known to be associated 
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with pre-60S subunits is Nmd3 (Ribbeck and Gorlich, 2002; Seiser et al., 2006; 
Zemp et al., 2009).  
There are several factors that are not associated with the mature 60S 
subunit that are part of the late cytoplasmic maturation of pre-60S subunits such 
as two GTPases: Lsg1/Kre35 and Eif1, two ATPases: Drg1 and Jjj1-Ssa1/Ssa2, a 
Zn2+ finger protein: Rei1, and a phosphatase: Yvh1 (Panse and Johnson, 2010).  
Most of these factors prevent the premature joining of 40S and 60S subunits until 
maturation is completed within the cytoplasm.  Of particular interest to this 
dissertation is the GTPase Efl1.  Shwachman-Bodian Diamond syndrome 
protein, SBDS, along with Efl1 are required for release of the anti-association 
factor eIF6 from pre-60S subunits in the cytoplasm (Menne et al., 2007; 
Valenzuela et al., 1982; Zemp et al., 2009). The pre-60S subunits that emerge 
from the nucleus contain the anti-association factor eIF6 and the hydrolysis of 
GTP by Efl1 in association with SBDS is required for eIF6 release so 60S 
subunits can participate in translation.  This release is also necessary for eIF6 to 
be recycled back to the nucleus to function in transporting more pre-60S subunits 
to the cytoplasm (Basu et al., 2001; Finch et al., 2011; Gandin et al., 2008; 
Miluzio et al., 2009; Senger et al., 2001; Wong et al., 2011).
 Overview of translation
 Ribosomes and associated factors carry out the process of translation, the 
means by which nucleotide triplets within a mRNA dictate the synthesis of 
proteins via the genetic code.  Initiation is the process by which appropriate AUG 
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codons are identified in mRNAs and 80S ribosomes with initiator-tRNA bound to 
the P site are poised to begin the process of translational elongation.  The most 
tightly regulated steps of translation are typically found during the initiation phase 
(Jackson et al., 2010; Sonenberg and Hinnebusch, 2009).  There is both a 
canonical and non-canonical pathway of eukaryotic initiation.  The canonical 
pathway begins with the formation of the ternary complex including eIF2, GTP, 
and an initiator transfer RNA charged with a Met-tRNAMeti .  This complex  joins 
with a 40S subunit already bound to eIF1, which together with eIF1A, eIF3, and 
eIF5 form the 43S pre-initiation complex.  The mRNA is recognized through 5’-
cap structures by the eIF4F complex (eIF4F bound to eIF4E, eIF4G, eIF4A).  
This complex recruits the helicase eIF4B which can melt RNA secondary 
structures in an ATP-dependent fashion.  The 43S pre-initiation complex is then 
able to bind the mRNA/eIF4F complex and begins the process of scanning from 
the 5’ end of the mRNA towards the 3’ end until the complex finds a suitable 
AUG.  
 When the scanning complex localizes the AUG start codon in what will 
become the P (peptidyl) site, eIF1 is released, and eIF5 facilitates the hydrolysis 
of eIF2-GTP to eIF2-GDP.  After eIF2-GDP is released, the 60S subunit is able to 
join with the 48S complex and eIF5B subsequently mediates the release of eIF1, 
eIF3, eIF4B, eIF4F, and eIF5.  Next, eIF5B-GTP is hydrolyzed to eIF5B-GDP and 
eIF5B-GDP and eIF1A are released.  The 80S initiation complex is now ready to 
move to the elongation phase of translation.  After translation is complete, 
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termination occurs and many of the components of the translational machinery 
are recycled to participate in translation of other mRNAs (Jackson et al., 2010).  
 The alternative pathway of initiation involves mRNA elements called 
internal ribosome entry sites (IRES). Initially identified in viral mRNAs, these 
structures are able to recruit translational machinery without the normal initiation 
complex formation.  By employing these alternative strategies for translational 
initiation viruses are able to co-opt a host’s translational machinery to their own 
ends.  As is typically the case, it was eventually shown that host cells also 
employ these alternative strategies for translational initiation, but do so 
infrequently as forms of regulation at specific points in development, cell cycle 
progression, or in response to stress (Jackson et al., 2010).
 Peptide Bond Formation: Elongation
Once the 80S initiation complex is formed, and the Met- tRNAMet i  is in the 
P site, elongation can commence. The next codon downstream of the initiator 
AUG is used to specify which aminoacyl-tRNA will productively enter the  A 
(aminoacyl) site of the complex in a ternary complex with EF1A and GTP.  Once 
GTP is hydrolyzed and EF1A is released, a peptide bond is formed between the 
amino acids, then the ribosome shifts one codon toward the 3’ end catalyzed by 
EF2 and GTP hydrolysis, the A site is open and the newly synthesized peptidyl-
tRNA is translocated to the P site.  The deacylated tRNA formerly occupying the 
P site exits the ribosomal complex through the E (exit) site (Cech, 2000). 
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Elongation continues in most cases until the ribosome encounters a stop codon 
in the A site and termination occurs. 
 Numerous human diseases have been linked to defects in the production 
of ribosomes or in the process of translation.  The focus of this dissertation will be 
on diseases linked to defects in ribosome synthesis.  The inherited bone marrow 
failure syndromes as a class appear to be driven to varying extents by defects in 
the synthesis in ribosomes.  Some notable exceptions to this general statement 
are discussed in the following section.   
Bone Marrow Failure syndromes and Other Ribosomopathies
 Inherited Bone Marrow Failure syndromes (IBMFSs) are a heterogeneous 
array of diseases that have in common a failure to produce one or multiple blood 
lineages and are often associated with a significant cancer predisposition well 
above that of the general population.   The IBMFS also have certain unique 
features of presentation and pathophysiology characteristic of their specific 
disease.  The IBMFSs discussed in detail below include Fanconi Anemia (FA), 
Diamond Blackfan anemia (DBA), Dyskeratosis Congenita (DC), Shwachman 
Diamond syndrome (SDS), Severe Congenital Neutropenia (SCN), and Pearson 
Syndrome.   Many of these syndromes have molecular defects in ribosome 
synthesis that contribute to disease pathophysiology and are given the 
designation of “ribosomopathies.”  DBA and SDS will be the primary focus of this 
dissertation.    
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 Hematopoiesis
 Hematopoiesis refers to the generation of mature blood cells from the 
long-term hematopoietic stem cell (LT-HSC) progenitor.  In adults this takes place 
in the bone marrow where HSCs divide to form more HSCs, the self-renewing 
property common to all stem cells, as well as differentiate to form committed 
progenitors (Metcalf, 2007).   Mature cells of the hematopoietic system include 
lymphocytes, granulocytes, monocytes, megakaryocytes, and erythrocytes.  
Lymphocytes include both T and B cells central to immune system function. T 
cells are antigen recognition and antigen presenting cells whose final maturation 
takes place in the thymus, while B cells fully differentiate in the bone marrow and 
produce antibodies important in phagocytosis and the complement system of 
immunity.  Granulocytes, also called polymorphonuclear cells (PMN), include 
eosinophils released to sites of allergy or parasitic infection.  Neutrophils are 
phagocytic and engulf pathogens such as opsonized bacteria and use their 
specialized set of enzymes such as NADPH oxidases and myeloperoxidases 
(MPO) to generate ROS in phagolysosomes and destroy the bacteria. Basophils 
respond to inflammation and release heparin, an anticoagulant.    Monocytes 
differentiate into macrophages and dendritic cells in the spleen and function by 
phagocytosing pathogens.  The most common while blood cells in circulation are 
neutrophils. Megakaryocytes release platelets important in forming blot clots.  
Erythrocytes are the transporters of hemoglobin, the primary oxygen carrier in 
the body (Metcalf, 2007). 
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The first maturation step from the hematopoietic stem cell splits the 
lineages for lymphocytes (common lymphoid progenitor, or CLP) and all other 
blood cell types (common myeloid progenitor, or CMP).  The CLP will then 
differentiate into a lineage specific pre-B cell or pre-T cell. The differentiation of 
the myeloid lineage is much more complex.  The CMP first becomes either a 
MEP (megakaryocyte erythroid progenitor) or a GMP (granulocyte macrophage 
progenitor).  The MEP further differentiates into Meg-CFC and then 
megakaryocytes, which generate platelets, or BFU-E (burst forming units - 
erythroid).  The BFU-E give rise to CFU-E (colony forming units erythroid) and 
eventually mature erythrocytes.  The GMP further differentiates into either the 
Mast-CFC that will become a basophil, the eosinophil CFC (Eo-CFC), or the 
granulocyte macrophage CFC (GM-CFC). The GM-CFC differentiates into two 
lineages, the granulocyte CFC (G-CFC) that will become neutrophils or the 
macrophage CFC (M-CFC) that will become monocytes (Metcalf, 2007).  The 
process of differentiation is dependent not only on cytokines or growth factors 
that drive the formation of the various blood lineages, but also the complex 
stromal environment of the bone marrow niches through an interplay of multiple 
types of regulation of numerous cell types in the marrow  (Bianco, 2011).  Recent 
evidence obtained from mouse studies indicated that there are several classes of 
LT-HSCs with predispositions for differentiation toward specific blood lineages, 
adding additional levels of complexity (Cavazzana-Calvo et al., 2011).  Inherited 
bone marrow failure syndromes all have a pathological defect in one or multiple 
steps during the maturation process outlined above. 
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Diamond Blackfan Anemia: Pathophysiology
Diamond Blackfan anemia (DBA) is a macrocytic normochromic anemia 
that most commonly manifests in infancy.  In addition to red blood cell 
hypoplasia, up to 40% of patients also have a congenital defect, with 25% having 
multiple anomalies.  The most common anomalies are short stature, craniofacial 
defects, triphalangeal or bifid thumbs, and deformities of the urogenital and 
cardiovascular systems (Vlachos et al., 2008).  The first link between DBA and 
the ribosome came in 1999 when a chromosomal translocation in a DBA patient 
was shown to inactivate RPS19, (Ribosomal Protein of the Small subunit number 
19) a gene encoding a structural component of the 40S ribosomal subunit 
(Draptchinskaia et al., 1999).  RPS19 remains the most common target of 
inactivating mutations in DBA, compromising approximately 25% of the patient 
population.  To date, pathogenic mutations have been identified in nine additional 
genes encoding ribosomal proteins of both the large (60S: RPL5, RPL11, 
RPL35a, RPL26) and small (40S: RPS7, RPS10, RPS17, RPS24, RPS26,) 
subunit (Farrar et al., 2011; Gazda et al., 2012; Vlachos et al., 2008).  In each 
case, mutations identified are found in the heterozygous state indicating that 
DBA is the result of haploinsufficiency for the affected ribosomal protein.  The 
view of DBA as a ribosomopathy became inexorable when the gene responsible 
for the refractory anemia in patients with the myelodysplastic 5q - syndrome was 
shown to encode ribosomal protein S14 (RPS14) (Ebert et al., 2008).  Only 
limited genotype/phenotype relationships have been identified so far in DBA 
patients.  The most notable is that patients with RPL5 and RPL11 mutations in 
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general display a much more severe phenotype including a high prevalence of 
cleft lip and cleft palate.  
Though it has been over a decade since DBA pathogenesis was originally 
linked to deficiencies of ribosomal proteins, the mechanisms underlying disease 
pathophysiology, in particular the tissue specificity of disease presentation 
remain unclear.  It has been well established that reduced quantities of a 
ribosomal protein can interfere with the assembly of the subunit to which it is a 
part.   For example, cell culture models have shown that reducing the level of 
expression of RPS19 interferes with the biogenesis of 40S subunits and gives a 
well-defined signature of RPS19 dysfunction in pre-rRNA processing. This pre-
rRNA processing signature associated with RPS19 deficiency is also evident in 
cells from the bone marrow of DBA patients (Flygare et al., 2007).  Pre-rRNA 
processing signatures have been associated with other ribosomal proteins 
affected in DBA.  The specific signature for a given ribosomal protein will depend 
on which rRNA (or pre-rRNA) it becomes initially associated with, and also, in the 
case of the larger rRNAs, which sub-assembly domain of the rRNA contains the 
protein.  Together, these data indicate that ribosome assembly is defective in 
individuals haploinsufficient for ribosomal proteins, and defective ribosome 
assembly lies at the heart of DBA pathophysiology.
  Molecular Mediators of DBA 
 During normal ribosome biogenesis, ribosomal proteins and rRNA are 
joined in a specific temporal and spatial sequence to form mature ribosomal 
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subunits (Warner and McIntosh, 2009).  In order to coordinate the generation of 
ribosomes with the needs of the cell, there are multiple connections between 
ribosome synthesis and cell division, nutrient availability, and apoptosis (Dai and 
Lu, 2008; Dai et al., 2004; Fernandez et al., 2002; Lindstrom et al., 2007; Sun et 
al., 2007).  Ribosomal proteins that are synthesized in excess of that needed for 
subunit assembly are frequently rapidly degraded (Lam et al., 2007).  It has now 
become clear that certain ribosomal proteins have novel, extra-ribosomal, 
functions when they are not incorporated into ribosomal subunits (Warner and 
McIntosh, 2009).  Several of these ribosomal proteins influence the delicate 
balance between cell survival and apoptosis through their interactions with the 
oncogene MDM2 (murine double minute two oncogene, whose human ortholog 
is HDM2).  MDM2 is an E3 ubiquitin ligase that can target p53 for proteosomal 
degradation and is one of the exquisitely sensitive primary regulators of p53 
stability (Clegg et al., 2008).  RPL11, RPL5, RPL23, RPL26, RPS3, and RPS7 
are all capable of binding MDM2 during “ribosomal stress.” Ribosome stress can 
be induced by a variety of effectors including treatement with actinomycin D, an 
RNA polymerase I inhibitor.  Under these conditions ribosomal proteins are free 
to interact with and inhibit MDM2 resulting in p53 stabilization and activation 
(Chen et al., 2007; Dai and Lu, 2004; Dai et al.; Dai et al., 2004; Fumagalli et al., 
2009; Horn and Vousden, 2008; Ofir-Rosenfeld et al., 2008; Sun et al., 2007; 
Yadavilli et al., 2009; Zhang et al., 2003; Zhu et al., 2009). 
In addition to ribosomal proteins, there is growing evidence to suggest that 
5S rRNA plays a role in ribosome stress signaling.  The 5S rRNA is distinct in that 
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it is transcribed by RNA polymerase III independent of the rDNA repeat as 
transcribed by the polycistronic RNA polymerase I transcript containing the other 
three rRNAs.  5S rRNA forms a complex with RPL5, and possibly RPL11, prior to 
the incorporation of this subcomplex into the assembling 60S subunit (Zhang et 
al., 2007).  Intriguingly, the subcomplex of RPL5, RPL11, and 5S rRNA binds 
more effectively to MDM2 than each of the individual components alone.  The 
synergistic interaction of this subcomplex with MDM2 could potentially play a 
major role in signaling abortive assembly of the 60S ribosomal subunit leading to 
p53 stabilization and activation as shown in Fig 2. This observation is potentially 
of fundamental importance to mechanisms underlying DBA pathophysiology, 
because erythrocyte precursors in the bone marrow of patients show a pro-
apoptotic phenotype which appears linked to p53 activation (Lipton et al., 1986; 
Nathan et al., 1978; Ohene-Abuakwa et al., 2005; Perdahl et al., 1994).   Thus, 
this pathway is hypothesized to be the cornerstone linking defective ribosome 
assembly to the pro-apoptotic phenotype of erythroid progenitors in the marrow 
of patients with DBA. 
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 Fig. 2: The 5S rRNA subcomplex as a critical mediator of ribosome stress 
signaling to p53 activation. 
When ribosomal proteins become limiting, such as in the setting of ribosomal 
haploinsufficiency in DBA pathogenesis, ribosomal proteins are free and are 
capable of interacting with MDM2 leading to p53 activation.  In the setting of 
haploinsufficiency for a large subunit ribosomal protein the 5S rRNA subcomplex 
may play a critical role in ribosomal stress signaling.  It is less clear which factors 
play vital roles in ribosomal stress signaling when small subunit ribosomal protein 
genes are affected in DBA or when mutations are found in either the RPL5 or 
RPL11 genes (Lipton and Ellis, 2009).
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!! ! Previous Animal Models of DBA 
 Generation of an animal model that recapitulates both the hematological 
and ribosomal defects associated with DBA patients has proven challenging.   A 
knockout mouse would seem the obvious choice in a disease marked by 
haploinsufficiency for ribosomal protein genes.  The heterozygous Rps19 mouse 
model, showed no detectable phenotypes, and the homozygous mutant led to 
early embryonic lethality (Matsson et al., 2004).  The first animal models of DBA 
that showed a blood lineage defect were created in zebrafish (Danilova et al., 
2008; Uechi et al., 2008).  Zebrafish have several advantages as an animal 
model for hematology. The transparent embryos make iron-containing 
substances, such as the heme in the hemoglobin of mature red blood cells, 
easily visualized.   The externally fertilized embryos provide an easy conduit for 
over or under expressing a gene of interest.  Zebrafish models have allowed for 
high throughput drug screening and localization of genetic modifiers. Though 
many advances have been made possible through study of zebrafish models, 
there are also several important differences in zebrafish blood development 
when compared to human processes.  The sites of blood lineage development in 
zebrafish are far removed from their localization in humans.  Hematopoietic stem 
cells (HSCs) in zebrafish are found in kidney marrow rather than the bone 
marrow as in mammals (Carradice and Lieschke, 2008; Jing and Zon, 2011).   
 The first mammalian model of DBA with an erythroid defect was 
serendipitously discovered during a screen for mutations that cause dark-skinned 
footpads in mice (McGowan et al., 2008).   Two causative mutations in the screen 
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were identified as ribosomal protein genes, Dsk3 as Rps19, and Dsk4 as Rps20. 
Only Rps19 is a known DBA gene.  After this discovery, the authors identified a 
very mild anemia in the affected mice.  Subsequently, they reversed pathological 
findings in an Rps6 heterozygous knockout mouse by inhibition of p53 function, a 
common theme recognized among putative animal models of DBA (Ball, 2011; 
Boultwood et al., 2011; Danilova et al., 2008; Jaako et al., 2011; McGowan et al., 
2011).  The validity of an Rps6 heterozygous mouse to study DBA is diluted by 
the lack of an identified mutation in RPS6 in a DBA patient, as well as the 
specialized function of Rps6 as a downstream target fr phosphorylation by the 
mTOR pathway (Magnuson et al., 2012).  
A more recent mouse model expressed a Rps19R62W point mutation 
found in a DBA family pedigree. It has been hypothesized that this mutation may 
function in a dominant negative manner (Devlin et al.).   This particular model 
linked inducible expression of this modified allele in a normal mouse genetic 
background to some of the blood lineage defects seen in DBA patients but also 
differed in certain important respects.  These mice lack some of the key pre-
rRNA processing defects seen in DBA patients with known RPS19 mutations,  as 
well as a block in blood progenitor maturation at a different stage of development 
than those seen in bone marrow specimens from DBA patients (Flygare et al., 
2007).   Thus, none of the currently available animal models of DBA are entirely 
adequate and improvements are still needed.  Our contribution to this gap are 
represented in chapter two of the appendix, which details our role in the 
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validation of ribosome defects in a novel mouse model of DBA (Jaako et al., 
2011).
Shwachan Diamond syndrome (SDS)
Shwachman Diamond syndrome typically presents in early infancy, but 
has also been diagnosed in adolescents.  The most common presenting 
symptom is malabsorption of fat from the diet due to pancreatic insufficiency and 
the associated decrease in amylase, trypsinogen, and lipase production. The first 
case of SDS was described as pancreatic insufficiency with bone marrow 
dysfunction and the two symptoms remain the diagnostic criteria in the present 
day (Rothbaum et al., 2002; Shimamura and Alter, 2010; Shwachman et al., 
1964).  Most patients have a neutropenia that upon analysis of bone marrow 
samples reveals a hypocellular bone marrow with decreased myeloid 
progenitors, but the initial neutropenia often presents later than the symptoms of 
malabsorption. The neutropenia severity shows a wide range of variation among 
patients (Shimamura and Alter, 2010).  In addition to neutropenia, multiple other 
blood lineages can be affected in SDS, with more severe disease courses 
leading to aplastic anemia, eventual myelodisplastic syndrome (MDS), or acute 
myelogenous leukemia (AML) (Berthou et al., 1991; Shimamura and Alter, 2010).  
The most frequent causes of death in SDS patients are sepsis, due to the 
neutropenia, or AML. Unfortunately the median age of survival is currently 36 




 Biallelic mutations in SBDS (Shwachman Bodian Diamond Syndrome) 
have been identified in over 90% of SDS patients (Boocock et al., 2003). The 
disease is inherited in an autosomal recessive pattern. There are no cases 
associated with homozygous null mutations and homozygous loss of Sbds in 
mouse models is embryonically lethal (Zhang et al., 2006).  Most mutations are 
thought to be hypomorphic alleles that arose from conversion with an adjacent 
pseudogene SBDSP (Shammas et al., 2005).  The most common mutations are 
in exon 2, and include c.183_184insCT or c. 258+2T>C on separate genes, or 
the combination of the two mutations in the same gene. Seventy-six percent of 
patients have at least one of these three mutations and 62% have both (Boocock 
et al., 2003).  
SBDS Protein Functions
 The SBDS protein is evolutionarily conserved across eukaryotes and 
many archaebacteria (Boocock et al., 2003; Menne et al., 2007; Ng et al., 2009; 
Shammas et al., 2005).  First clues as to the function of SBDS came from the 
finding that certain archaebacterial orthologs were found in operons containing 
genes involved in RNA metabolism.  Included among these genes were ones 
encoding proteins involved in pre-rRNA processing.  Studies on the yeast 
ortholog of SBDS, Sdo1, revealed a role for Sdo1 in the maturation of 60S 
ribosomal subunits (Menne et al., 2007).  Specifically, Sdo1 plays a role in 
releasing the anti-association factor Tif6 from nascent pre-60S subunits entering 
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the cytoplasm.  The failure to release Tif6, also limits its recycling back to the 
nucleus where it is involved in the nucleocytoplasmic transport of pre-60S 
subunits.  These combined effects severely limit the production of functional 60S 
subunits in cells depleted of Sdo1.  Recent studies in mammalian cells have 
shown related functions for SBDS in the maturation of 60S ribosomal subunits 
(Wong et al., 2011).  
 In addition to its role in the maturation of 60S ribosomal subunits, SBDS 
has been implicated in a number of additional cellular processes  The SBDS 
protein has been shown to colocalize with the mitotic spindle, and cell models 
expressing mutant versions of the protein analogous to SDS patient mutations 
have been shown to have altered SBDS cellular localization. This is proposed as 
an instigator of genomic instability in SDS, a putative pathway leading to AML 
(Austin et al., 2008; Maserati et al., 2009; Orelio et al., 2009).  Changes in 
cellular localization are hypothesized to occur via modifications in the 
SUMOlyation domain at the C-terminus of the protein (Orelio et al., 2011).  Bone 
marrow progenitor cells show an increased propensity for apoptosis, and cellular 
models of SDS have shown an increased sensitivity to Fas (a ligand for death 
domain receptors that activate downstream caspase cleavage and result in 
apoptosis) and changes in cellular localization of Fas when stimulated 
(Rujkijyanont et al., 2009; Rujkijyanont et al., 2008; Watanabe et al., 2009).
 Other changes in cell function with mutations in SBDS include the 
decreased ability of neutrophils to polymerize F-actin in response to appropriate 
cellular stimuli (Orelio and Kuijpers, 2009), increased reactive oxygen species 
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(ROS) production (Ambekar et al., 2010), and changes in the bone marrow 
stromal environment (Raaijmakers et al., 2010).  Bone marrow from SDS patients  
show an intrinsic defect in the maturation of blood progenitors (Dror and 
Freedman, 1999).  The dyscrasias found in patient bone marrow samples are 
due to defects not only in the hematopoietic cells, but also in the stromal cells 
that support the differentiation of stem cells as evidenced by bone marrow 
transplant studies in animal models (Rawls et al., 2007).  Clearly, any of these 
multiple functions of the SBDS protein could contribute to the clinical features of 
SDS.
Dyskeratosis Congenita (DKC)
Dyskeratosis Congenita occurs in X-linked as well as autosomal dominant 
and autosomal recessive inheritance patterns.  Clinical findings include 
dystrophic nails, oral leukoplakia, lacy reticular pigmentation, lacrimal duct 
stenosis, sparse and/or gray hair, poor dentition, development delay, esophageal 
stenosis, and avascular necrosis of the hip (Alter, 2007; Berthou et al., 1991; Liu 
and Ellis, 2006; Narla and Ebert, 2010; Savage and Alter, 2009; Savage et al., 
2009; Tamary et al., 2010).  Criteria for diagnosis include measurement of 
telomere length, as DKC patients usually have telomeres that fall within the very 
lowest percentile of telomere length for age matched controls.  With age their risk 
for aplastic anemia and MDS increases much more dramatically than the rest of 
the population (Alter et al., 2010; Alter et al., 2009; Du et al., 2009; Gadalla et al., 
2010; Heiss et al., 1998; Savage and Alter, 2008, 2009; Savage et al., 2009; 
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Tamary and Alter, 2007; Tamary et al., 2010).  Bone marrow inspection usually 
reveals hypocellular bone marrow with decreased megakaryocytes.  Bone 
marrow failure is the leading cause of death in DKC (Narla and Ebert, 2010).  
Pathogenic mutations in DKC patients have been identified in six genes that all 
function in the maintenance of telomeres.  Many of the genes mutated in DKC 
produce products that perform multiple functions in the cell.  Mutations in DKC1 
have an X-linked recessive inheritance pattern, and this particular mutation leads 
to defects in ribosome biogenesis due to the functions of dyskerin as a member 
of the snoRNP complex that is required for psuedouridylation of pre-rRNA.  In 
addition to its function in maturation of rRNA, dyskerin is also associated with 
other proteins, such as TERT,  and RNAs, such as TERC, to form the telomerase 
complex that protect the telomeres found at the end of chromosomes (Heiss et 
al., 1998; Knight et al., 1998).  Mutations in TERT can be inherited in autosomal 
dominant and autosomal recessive inheritance patterns, while TINF2 and TERC 
have only been shown in autosomal dominant patterns, and N0P10/NOLA3 and 
NHP2/NOLA2 are autosomal recessive.  Except for the mutations in dyskerin 
none of the other mutations in DKC genes are thought to affect ribosome 
function.  Interestingly, the X-linked form of the disease is typically more severe 
than the other forms indicating that effects on ribosome synthesis can modify the 
clinical phenotype in this, and perhaps other disorders.    
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Cartilage Hair Hypoplasia (CHH)
Cartilage Hair Hypoplasia (CHH) was first described as a dwarfism in an 
isolated Amish population (McKusick et al., 1965).  In such isolated Amish 
populations and certain Finnish populations there is an increased incidence of 
CHH, but it is very rare in the general population (Makitie, 1992; Ridanpaa et al., 
2002).  It most commonly presents with skeletal dysplasias, immune dysfunction, 
hypoplastic hair, and increased cancer susceptibility.  One or multiple blood 
lineages can be affected, with cells of the myeloid lineage being most commonly 
affected (Ganapathi and Shimamura, 2008).  Autosomal recessive inheritance 
patterns are seen with mutations in RMRP encoding the RNA component of 
RNAse MRP (mitochondrial RNA processing complex).  This RNase has a 
number of targets including the cyclin B2 mRNA, mitochondrial RNA, and a 
cleavage within ITS1 of 45S pre-rRNA giving rise to the mature 5′ end of 5.8S 
rRNA.   Mutations in RMRP that predominantly affect pre-rRNA processing most 
commonly cosegregate with skeletal dysplasias, whereas mutations that 
selectively affect cyclin B2 mRNA cleavage give rise to the immune deficiencies 
(Theil et al., 2011).  Management is primarily supportive care, but transplant may 
be indicated in very severe cases (Narla and Ebert, 2010).  
Treacher Collins syndrome (TCS)
Treacher Collins syndrome (TCS) is usually recognized shortly after birth 
due to its characteristic set of facial features and was initially described by an 
ophthalmologist over a century ago (Collins, 1900).  Deformations are caused by 
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inadequate migration of neural crest cells during fetal development (Dixon et al., 
2006) leading to downward lateral slanting palpebral fissures (outer corners of 
the eyelid), abnormal ear development with hearing loss as a common side 
effect, hypoplasia of the maxillary and malar portions of the skull leading to a 
flattening of the mid-face and micrognathia (abnormally small jaw) and cleft 
palate (Narla and Ebert, 2010).   The management of these patients requires the 
attentive care of numerous types of physicians due to the complications that are 
associated with such physical anomalies (Posnick and Ruiz, 2000).  Many of the 
craniofacial defects seen in TCS are reminiscent of those seen with RPL5 and 
RPL11 mutations in DBA (Narla and Ebert, 2010).  
Mutations in the gene TCOF1 that encodes the protein treacle were linked 
to this autosomal dominantly inherited condition (Jill Dixon, 1996).  Treacle binds 
to rDNA and upstream binding factors required for the transcription of the 45S 
polycistronic pre-rRNA sequence (Valdez et al., 2004).  It also appears necessary 
for methylation of the 45S pre-rRNA.  More recently, mutations in genes encoding 
critical shared polypeptides between RNA polymerase I and III have been 
identified in TCS patients (Valdez et al., 2004).  This observation indicates that 
defects in RNA polymerase I transcription likely underly disease pathophysiology.  
A mouse model haploinsufficient for Tcof1 demonstrated that the defects in 
neural crest cell migration and neural epithelial apoptosis are instrumental in 
creating the physical findings pathognomonic of TCS (Dixon et al., 2006).  The 
craniofacial defects can be rescued by inhibiting p53 function during fetal 
development, even if the ribosomal defects are not corrected (Jones et al., 2008). 
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One of the more surprising aspects of the relationship between TCS and 
DBA is the fact that TCS patients do not exhibit bone marrow failure.  The 
pathophysiologic mechanism underlying current views of DBA involve free 
ribosomal proteins interacting with MDM2 to activate p53.  Much of the 
experimental support for this mechanism comes from in vitro cell culture work 
using Actinomycin D, an inhibitor of RNA polymerase I (Aktipis and Panayotatos, 
1981; Casse et al., 1999).  Nevertheless, these studies seem more relevant to 
the pathophysiologic mechanisms underlying TCS.  How then can we reconcile 
the fact that investigators in both fields appear to be employing the same 
pathophysiologic mechanisms for distinct diseases?  While there is some overlap 
in clinical presentation between the two disorders, specific craniofacial anomalies 
observed in DBA are restricted to specific ribosomal protein genotypes, whereas, 
potentially even more critically TCS lacks an associated bone marrow failure 
(Shimamura and Alter, 2010).  Clearly, investigators are missing something when 
ribosomal protein defects give rise to one disease and ribosomal RNA defects 
give rise to another and both disease phenotypes can be rescued by inactivating 
p53.    
Fanconi Anemia (FA)
Fanconi Anemia, FA, is the most commonly diagnosed IBMFS 
(Shimamura and Alter, 2010).  It presents most commonly as pancytopenia with a 
hypocellular bone marrow.  Other diagnostic features include an increased MCV 
(mean corpuscular volume) and increased HbF (fetal hemoglobin) (Ameziane et 
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al., 2008; Soulier, 2011).  More than 60% of patients have at least one congenital 
anomaly; the most common of which is short stature followed by café au lait 
spots, and hypo or hyperpigmentation.  Approximately one third of patients have 
radial defects involving the thumbs (Shimamura and Alter, 2010; Soulier, 2011). 
The cancer risk for Fanconi Anemia patients is 50 times higher than the general 
population, and the risk for MDS is increased 5,000 times. The most common 
malignancies in order of incidence are AML, head and neck squamous cell 
carcinoma, liver cancers, and vaginal squamous cell carcinoma (Rosenberg et 
al., 2004; Rosenberg et al., 2005).  
Thirteen genes have been identified as FA genes. With the exception of 
FANCB, which is X-linked, the remainder are inherited in an autosomal recessive 
fashion (FANCA, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG/
XRCC9, FANCJ, FANCJ/BACH1/BRIP1, FANCL, FANCM, FANCN/PALB2).  All of 
the FA linked genes are known to function in the repair of interstrand crosslinks in 
DNA (Alter et al., 2007; Andreassen et al., 2004; Bakker et al., 2009; de Winter 
and Joenje, 2009; Fagerlie et al., 2001; Meetei et al., 2003; Moldovan and 
D'Andrea, 2009; Nakanishi et al., 2002; Pichierri et al., 2004; Singh et al., 2009; 
Taniguchi et al., 2002; Wang, 2007; Wang et al., 2007).  None of the Fanconi 
genes are known to function in ribosome synthesis.  Diagnostic criteria for FA 
include testing of patient derived cells for extreme sensitivity to DNA crosslinking 
agents, followed by sequencing of the known FA genes.  Hematopoietic stem cell 
transplant is the only curative therapy for this disease, though it only corrects the 
anemia.  
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Severe Congenital Neutropenia (SCN)
Severe congenital neutropenia patients are usually diagnosed due to an 
infection, abscess, or pneumonia.  The only defect associated with this illness 
identified presently is a defect in the promyelocyte/myelocyte stage of 
differentiation of neutrophil precursors.  Multiple genes have been linked to SCN 
but the two most commonly affected are ELA2 or ELANE genes.  ELANE and 
ELA2 encode neutrophil elastase enzymes which are the major secretory 
proteins in neutrophils (Dale et al., 2006; Dale et al., 2000; Grenda et al., 2007).  
The heterozygous mutations found associated with SCN are typically missense 
mutations that interfere with protein folding in the endoplasmic reticulum.  
Because the overall secretory load is so great in neutrophils and these proteins 
represent such a high fraction of the total secretory pool, their misfolding causes 
ER stress of such severity that maturation arrest occurs and cells undergo 
apoptosis (Germeshausen et al., 2009a; Germeshausen et al., 2009b; Parikh 
and Bessler, 2012; Skokowa et al., 2009; Tamary et al., 2010; Welte and Zeidler, 
2009; Xia and Link, 2008; Zeidler et al., 2009).  Treatment with G-CSF 
(granulocyte-colony stimulating factor) or stem cell transplantation for patients 
that don’t respond are the current standards of care for this  disorder (Shimamura 
and Alter, 2010).  
Other Less Common IBMFS
Pearson syndrome (PS) is another IBMFS that is characterized by anemia 
and exocrine pancreatic insufficiency, originally described in 1979 (Pearson et al., 
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1979).  It is often fatal in infancy.  Patients that survive past early neonatal life 
develop symptoms similar to Kearns-Sayre Syndrome, which is a mitochondrial 
myoencephalopathy (a disorder of muscle and brain tissues) (McShane et al., 
1991; Rotig et al., 1990; van den Ouweland et al., 2000). Patient samples were 
found to have large deletions and/or rearrangements in mitochondrial DNA which 
disrupt energy metabolism. This preferentially affects tissues requiring a high 
threshold of mitochondrial function like the central nervous system and skeletal 
muscle (Baerlocher et al., 1992; Blaw and Mize, 1990; Cormier et al., 1990; 
Kleinle et al., 1997; Lee et al., 2007; Niaudet et al., 1994; Santorelli et al., 1996; 
van den Ouweland et al., 2000).  
The bone marrow failure and pancreatic insufficiency in Pearson 
syndrome is reminiscent of SDS, but there are significant differences.  Pearson 
syndrome patients have a sideroblastic anemia.  Ringed sideroblasts are 
nucleated red cells that did not mature before leaving the bone marrow.  They 
produce a granular staining with dyes to visualize iron, because iron granules 
form deposits in the mitochondria around the nucleus in these cells. This 
perinuclear arrangement is what forms the ring of the ringed sideroblast.   
Sideroblasts are also evident in X-linked sideroblastic anemia caused by defects 
in the gene encoding δ-amino levulinic acid synthase.  This enzyme is 
mitochondrial and performs the first step in the synthesis of heme.  The iron 
deposits formed in this disease result from the lack of protoporphyrin IX 
production.  In the absence of protoporphyrin IX, iron that would normally be 
used for heme synthesis deposits within the organelle giving rise to the ringed 
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sideroblasts (Cotter et al., 1992; Cotter et al., 1994; Ferreira, 1993; Mantzourani 
et al., 1995; Pagon and Bird, 1993; Pearson et al., 1979; Raskind et al., 1991; 
Sutherland et al., 1988).  Mitochondrial dysfunction in bone marrow progenitors 
in Pearson’s syndrome presumably disrupts protoporphyrin IX synthesis, 
explaining the sideroblasts seen in this disease.   Also, SDS patients have a 
hypocellular bone marrow and fatty infiltration of the pancreas, while Pearson 
Syndrome patients usually have normocellular bone marrow with fatty 
vacuolization (Blatt et al., 1994) and fibrotic changes in the pancreas 
(Shimamura and Alter, 2010).  In contrast, there are no reports of sideroblasts 
associated with anemia in Shwachman Diamond syndrome patients.  While 
these observation emphasize the differences between Pearson Syndrome and 
SDS, we feel that the work described in this dissertation indicates it may be 
worthwhile to look more carefully at the relationship between these two disorders. 
Amegakaryocytic thrombocytopenia (CAMT) is a deficiency of 
megakaryocytes whose normal function is to produce platelets.  Children usually 
present with symptoms of a clotting disorder such as infants with excessive 
bruising.  It Is not uncommon for patients to be diagnosed as adolescents or 
adults after development of a secondary condition such as aplastic anemia or 
MDS without prior recognition of the initial deficit in megakaryocytes (Shimamura 
and Alter, 2010).  Biallelic mutations in the gene encoding the thrombopoietin 
receptor, MPL, have been found in the majority of patients (Ihara et al., 1999). In 
a knockout mouse model deficient in mpl it was discovered that the receptor, in 
addition to its function in the production of megakaryocytes (Bartley et al., 1994; 
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de Sauvage et al., 1994; Gurney et al., 1994; Kaushansky et al., 1994), is also 
central to the maintenance of pluripotent bone marrow progenitors (Alexander et 
al., 1996a; Alexander et al., 1996b).  
Thrombocytopenia absent radii is another thrombocytopenia that differs 
from CAMT because of the associated congenital defect in its title. These 
patients lack radii bilaterally but still develop thumbs, though they are 
nonfunctional (Thompson et al., 2001). This is an important distinguishing 
characteristic from FA in which patients without radii always have associated 
thumb defects (Shimamura and Alter, 2010). 
Dissertation Overview
 As a group, IBMFS show multifactorial pathophysiology with frequent links 
to ribosome biology. Significant overlap in the clinical features of these disorders 
tends to complicate diagnoses, making it difficult to differentiate one from another 
based only on clinical parameters.  Considerable insight into molecular 
underpinnings of these diseases has been gained in recent years but many 
questions remain unanswered. Further, this understanding at the molecular level 
has not translated into dramatic improvements in diagnostic modalities, improved 
treatments, or substantial improvements in various prognostic parameters. This 
dissertation will focus on two specific IBFMS both of which arise to varying 
extents from defects in ribosome synthesis.  The first portion of this dissertation 
will discuss the identification of a new ribosomal protein gene involved the 
pathogenesis of DBA and provide a facile assay to screen patients for mutations 
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in genes encoding large subunit ribosomal proteins.  These studies also 
investigate the putative molecular mediators responsible for the increased p53 
activation shown in numerous DBA models. 
 The second portion of the dissertation will focus on SDS. It will include 
descriptions of generation of a mammalian model for SDS in an erythroleukemic 
human cell line and the functional consequences of depleting cells of SBDS. The 
concepts envisioned in this chapter were the direct result of work performed in a 
yeast model of SDS developed by Dr. Joseph Moore IV and Dr. Steve Ellis that 
first identified the changes in respiration associated with loss of SDO1, the yeast 
ortholog of SBDS. This part of the dissertation investigates a potential link 
between changes in cellular metabolism and mitochondrial dysfunction in SDS 
that has not been previously examined.  
 Given the heterogeneous nature of IBMFS several methods of 
investigation were initially pursued before the particular methods used in the 
body of the dissertation were chosen. Those portions of my laboratory work not 
contained within the body of the text are located in appendix one. This includes 
previously published work on an inducible shRNA mouse model that led to 
decreased RPS19 protein expression and is arguably the most phenotypically 
accurate animal model for DBA developed to date (Jaako et al., 2011) as well as 
additional work in the mES cell model introduced in chapter three that did not 





 All human samples were collected using protocols necessary for the 
protection of human subjects and in compliance with institutional guidelines.  
Whole blood samples (ranging in volume from 1.5-8 ml) were collected by 
personnel at the patient’s representative institution in vacutainer tubes treated 
with sodium heparin to prevent clotting.  The samples were then catalogued and 
shipped to the University of Louisville devoid of identifying patient characteristics.  
Initial experiments were performed on samples from the proband, her unaffected 
parents, and a healthy volunteer all of which were collected at Loma Linda 
University.  Subsequent samples including patients with characterized RPL5 and 
RPL35A mutations were obtained from Dr. Adrianna Vlachos at the Feinstein 
Institute for Medical Research in New York and Dr. Jason Farrar at Johns 
Hopkins University, respectively.  
Buffy Coat Preparation of Mononuclear Cells and Stimulation with ConA
 All samples involving human blood were treated as potentially hazardous 
materials and necessary precautions were taken.  All centrifugation steps were 
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carried out at room temperature.  Whole blood was removed from vacutainer 
tubes and placed in sterile 50 ml conical tubes.  The blood was then diluted with 
an equal volume of sterile PBS (Mediatech, VWR).  Three ml of Ficoll reagent 
(GE Healthcare) was added to the bottom of 15 ml conical tubes and 4 ml of 
diluted blood carefully layered onto the Ficoll at an angle to prepare an 
appropriate interface and maximize cell separation.  Aliquots of each sample 
were centrifuged at 400 x g for 40 minutes with the acceleration set to 1 and the 
brake set to 0.  All but 1 ml of the serum layer on the top of the gradient was 
aspirated with a 5 ml pipette and then the buffy coat (white fluffy phase) 
containing mononuclear cells was collected very carefully and slowly to avoid 
contamination of the buffy coat with other cellular layers.  The resulting buffy coat 
was placed in a fresh 15 ml sterile conical tube and resuspended in a total 
volume of 14 ml with sterile PBS.  An aliquot was taken from this solution for 
counting in a 1:1 solution with trypan blue (MP Biomedicals) in a hemocytometer 
(Hausser Scientific) to determine cell numbers in each sample.
The cells were harvested by centrifugation at 1500 rpm for 10 minutes and 
then suspended in RPMI-C.  RPMI-C was generated from RPMI 1640 
(Mediatech, VWR) with the addition of 10% FBS (Mediatech-VWR, heat 
inactivated), 50 U/ml penicillin (Invitrogen), 50 µg/ml streptomycin (Invitrogen), 
0.01M HEPES pH 7.4 (Invitrogen), and 2 mM L-glutamine (Glutamax- 
Invitrogen).  Immediately before use, concanavalin A (ConA), was added to a 
final concentration of 5 µg/ml (Sigma Aldrich, prepared as a stock in RPMI at 5 
mg/ml, stored at -20oC, and diluted 1:1000 for use).  Cells were diluted to a 
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concentration of 2x106 cells/ml.  Cells were stimulated with ConA for 96 hours at 
37oC with 5% CO2 in air in a humidified atmosphere.  After 96 hours cells were 
harvested using QIAshredder columns to lyse cells and remove cell debris.  An 
AllPrep kit from QIAgen was used for the extraction of RNA, DNA, and protein 
from the samples.  The manufacturer’s instructions were followed with the 
following modifications: fresh β-mercaptoethanol was added with each cell 
preparation rather than adding to the stock solution, RNA was eluted in a final 
volume of 30 µl and DNA was eluted in a final volume of 100 µl.  
Northern Blotting
RNA was quantified using the Take3 Synergy plate-reader system (Applied 
Biosystems) and equal amounts of RNA were fractionated by electrophoresis on 
1.5% formaldehyde-agarose gels as previously described (Flygare et al., 2007).  
Typically, 5-10 µg of total RNA in a final volume of 9 µl of diethylpyrocarbonate-
treated (1%) water, was mixed with 33 µl of RNA sample buffer: 1.2 X MOPS 
(10X MOPS; 0.4M 3-(N-morpholino) propane-sulfonic acid, 100 mM sodium 
acetate, and 10 mM EDTA adjusted to pH 7 with sodium hydroxide), 7.9% 
formaldehyde, 60% formamide, and 0.06 mg/ml ethidium bromide.  After mixing 
the samples were heated to 65° for 15 minutes and 4 µl RNA dye (50% glycerol, 
1 mM EDTA, 0.4 % bromphenol blue, 0.4 % xylene cyanol) was added.  RNA 
fractionated in this manner stains with ethidium bromide in the sample buffer so 
there is no need for subsequent staining of gels after separation.  Gel images 
were captured by a Bio-Doc-It Imaging System.  RNA was subsequently 
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transferred to zeta-probe (BioRad), washed in 2x SSC (20X SSC: 3M NaCl, 0.3M 
NaCitrate pH 7.4) and 1%SDS (prepared as a 10% w/v solution with powder from 
Fisher) for 4 or more hours at 55°C and prehybridized overnight at 37° in Ambion 
ULTRAhyb oligo hybridization buffer.  Membranes were hybridized overnight with 
radiolabeled probes shown in Table 1.  Membranes were subsequently washed 
with 6 X SSC at 37° and placed in phosphorimager cassettes for image capture 
using typhoon imaging software and band intensity quantified using Imagequant 














increased 21S (Flygare et 
al., 2007)
M: 5’ CAG GCC GCC GCT CCT CCA 
CAG TCT C 3’
H: 5’ CCT CGC CCT CCG GGC TCC 






increased 32S and 12S 
(Rouquette et al., 2005)
M: 5’ GAC GCG ATT GAT CGT CAA 
CCG ACG CT 3’
H: 5’ GGG GCG ATT GAT CGG CAA 
GCG ACG C 3’
ITS2b ITS2 RPL5, RPL11 
increased 32S and 12S
(Gazda et al., 2008)
M: 5’ CTG CGA CGC AAC TCC CAG 
CCG CGC A 3’
H: 5’ CTG CGA GGG AAC CCC CAG 
CCG CGC A 3’
ITS2 d/e ITS2 RPL5, RPL11
increased 32S and 12S
(Gazda et al., 2008)
H 5’ GCG CGA CGG ACG ACA CCG 
CGG 3’ 
5S 5S Mature rRNA  
(Choesmel et al., 2007; 
Rouquette et al., 2005)
H: 5’ CAG ACG AGA TCG GGC GCG 
TTC 3’
M: Used human probe 
5.8S 5.8S Mature rRNA
(Choesmel et al., 2007; 
Rouquette et al., 2005)
H: 5’ CAA TGT GTC CTG CAA TTC AC 
3’
M: Used human probe 
18S 18S Mature rRNA  
(Choesmel et al., 2007; 
Rouquette et al., 2005)
H: 5’ GCA TGG CTT AAT CTT TGA 
GAC AAG CA 3’
M: used human probe 
!!
Table 1: Northern blot probes used for the identification of pre-rRNA 
processing intermediates and mature rRNAs 
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Cell Culture and Cytokines
All mammalian cell lines were cultured at 37oC with 5% CO2 in a 
humidified atmosphere. 
TF-1 DBA Model 
The TF-1 erythroleukemic cell lines were maintained in RPMI 1640 
(Mediatech) supplemented with 10% heat inactivated fetal bovine serum (FBS), 
(Mediatech), 1% P/S, (Invitrogen) and 5 ng/ml GM-CSF (Peprotech).  The TF-1 
cell line with a doxycycline inducible shRNA targeting RPS19 mRNA was 
developed in the Karlsson laboratory as previously described (Miyake et al., 
2005).  Doxycycline (Sigma Aldrich) was added to cultures at a final 
concentration of 5 ng/ml for four to seven days before cells were harvested for 
subsequent experiments.
TF-1 SBDS Model 
 The TF-1 erythroleukemic cell lines were maintained in RPMI 1640 
(Mediatech) supplemented with 10% heat inactivated fetal bovine serum 
(Mediatech), FBS, 1% penicillin/streptomycin, P/S, (Invitrogen) and 5 ng/ml 
GMCSF (Peprotech).  TF-1 cell lines transduced with lentiviral vectors (Sigma 
Aldrich) targeting SBDS mRNA were developed by Gulay Sezgin in the 
laboratory of Dr. Johnson Liu.  Briefly, TF-1 cells were transduced at a cell 
density of 1x106 cells with lentiviral particles [(200 µl of 107 TU/ml) purchased 
from Sigma Aldrich] using 6µg/ml polybrene.
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Sequences included in the lentiviruses targeting SBDS are:
#1: 5′ - CCGGGCCAAATACTTGCTTAAACTACTCGAGTAGTTTAAGCAAGTAT
TTGGCTTTTTG - 3′ 
#2: 5′ - CCGGGCCAACAGTTAGAAATCGTATCTCGAGATACGATTTCTAACTG
TTGGCTTTTTG - 3′ 
 To establish stable cell lines, transduced TF-1 cells were placed under 
puromycin selection at 5 µg/ml (Fisher).  Multiple clones for each of the two 
shRNA sequences used to reduce SBDS expression were established.  
Mouse Embryonic Stem Cell Models of DBA 
Mouse embryonic stem cell (mES) lines where one of two known DBA 
genes were inactivated by gene trap technology were purchased commercially.  
Two sets of cell lines with haploinsufficiency for Rps19 were obtained from the 
Mutant Mouse Regional Resource (MMRR) and one cell line mimicking 
haploinsufficiency for Rpl5 was obtained from the German Gene Trap 
Consortium.  A parental control cell line was also obtained for each gene trap.  
The S17-10H1 cell line was generated from the AK7.1 mouse embryonic stem 
cell parental line by electroporation of the ROSAFRY gene trap retroviral 
construct in intron 2 of a single copy of Rps19 (Fig. 3).  A “rescue vector” to 
restore Rps19 protein expression was generated  by inserting the Rps19 cDNA 
sequence into the pCMV6-A-Puro expression vector (Origene).  This rescue 
plasmid called ORF-S17 was electroporated into the mES cells (Bio-Rad Gene 
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Pulser).  An empty vector control cell line was created in the same fashion.  The 
cell line heterozygous for Rps19 transfected with the empty vector is called 
“EMT-S17.” This cell line should mimic Rps19 haploinsufficiency observed in 
DBA patients.  Cells with the rescue vector “ORF-S17” should mimic healthy 
controls.  Both cell lines express a gene for puromycin resistance.  
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Fig. 3: Insertion of the ROSAFARY gene trap vector between exon 2 and 
exon 3 of Rps19 gene created the S17 gene trap cell line. 
The ROSAFARY gene trap vector was used to create a genetrap library that has 
one gene in each cell line that is interrupted by this retrovirus.  The AK7 mouse 
parental line has the inserted retroviral sequence located between exons two and 
three of the Rps19 gene, leading to two fusion genes.  The first fusion gene is 
referred to as a promoter trap and creates a fusion gene between the gene being 
disrupted and the β-geo gene coding for neomycin resistance.  Transcription is 
halted downstream of β-geo by a poly(A) addition sequence.  Since this fusion 
gene expresses only exons 1 and 2 of Rps19 it is unlikely to lead to a functional 
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product.  The second fusion gene links the hyg  gene, a selection marker,  to 
exons 3-6 of Rps19.  Again, this fusion gene is unlikely to produce a functional 
Rps19 protein.  
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 The second Rps19 gene trap model, termed YHC074, was also purchased 
from MMRC and was generated using the parental mES cell line E14Tg2a.4.  
The pGT0lxf gene trap vector in this cell line is inserted into intron 3, between 
exon 3 and 4 of the Rps19 gene (Fig. 4).  The third mES gene trap cell line, 
D050B12, was purchased from the German Gene Trap Consortium and was 
generated from the parental TBV-2 mES cell line.  This cell line was created 
using the ROSAFRY gene trap vector inserted into intron 3 of the Rpl5 gene (Fig. 
4).  
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Fig. 4: Location of gene trap insertions in mES cell lines used. 
The S17 cell line contains the insertion between exons two and three of Rps19. 
The YHC074 cell line contains a gene trap insertion in between exons three and 
four of Rps19.  The D050 cell line contains a gene trap insertion in between 
exons three and four of the Rpl5 gene.  (Gene trap technology is described in 
greater detail in the legend of Fig. 3). 
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 Mouse embryonic stem cells were cultured under the conditions 
established by stem cell technologies (www.stemcell.com).  Tissue culture dishes 
were coated by adding an excess of 0.1% gelatin solution from Stem Cell 
Technologies (3 mL for a T25 flask, with proportional increases depending on 
dish size), allowing the plate to sit at room temperature in the biosafety cabinet 
for 20 minutes, removing excess gelatin, and allowing the plates to dry before 
use.  Maintenance media was prepared using DMEM high glucose (Invitrogen) 
supplemented with 15% stem cell grade FBS (Stem Cell Technologies), 100 µM 
non-essential amino acids (Stem Cell Technologies), 100 U/ml penicillin, 10 µg/
ml streptomycin (Invitrogen), 2 mM glutamine (Glutamax ©Invitrogen) 100 µM 
monothioglycerol (MTG; Sigma), and 10 ng/ml  mouse leukemia inhibitory factor 
(mLIF; Stem Cell Technologies).   A stock solution of mLIF was made fresh on the 
day of media preparation by diluting 1:100 in DMEM and adding 43 µL to each 50 
ml aliquot of media.  Media was sterile filtered prior to addition of mLIF and was 
kept for no more than one week at 4oC.  The TBV-2 and its derived line, 
D050B12, were originally maintained on an embryonic fibroblast feeder layer 
(Stem Cell Technologies) in the presence of mitomycin C (Sigma) before being 
plated on gelatin coated plates without fibroblasts to develop feeder independent 
cell lines.  All experiments were performed on feeder independent cell lines.  The 
other two sets of mES cells were always plated without feeders on gelatin coated 




 All animals were maintained at Lund University, Sweden by the laboratory 
of Stefan Karlsson. Tssues and cell lines were shipped to the University of 
Louisville for further study.  Briefly, embryos were developed with one or two 
copies of either sequence “B” or sequence “D” shRNA designed to target Rps19 
mRNA under the control of a tet-on promoter located in the collagen A1 locus 
(Jaako et al., 2011). Animals with single copies of the inducible shRNA (B/+ or D/
+) were termed “single dox,” and those with two copies of the inducible shRNA 
(B/B or D/D) were demarcated as “double dox.” Liver and bone marrow samples 
from mice given doxycycline in their drinking water for two weeks were sacrificed 
and used for the experiments outlined below.  
 Mouse embryonic fibroblasts (MEF) from the Karlsson mice were 
maintained in DMEM media (Mediatech), supplemented with 10% FBS 
(Mediatech), and 1% P/S (Invitrogen).  To decrease Rps19 expression, 
doxycycline (Sigma Aldrich) was added to a final concentration of 1 µg/ml or 5 
µg/ml for seven to fourteen days before sample harvest (Jaako et al., 2011).
Cell Viability and Rescue with NAC
 Cell counts were performed by taking an aliquot of cells and diluting with 
an equal volume of Trypan Blue (MP Biomedicals) and adding 10 µL of the 
resulting solution to a hemocytometer (Hausser Scientific) to determine cell 
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number.  All viability experiments were performed in triplicate with three separate 
counts obtained for each experiment. 
After four days of growth, the cell cultures were treated with various 
concentrations of N-acetyl cysteine (Sigma). The stock solution of 500 mM was 
prepared in RPMI media and dilutions made to a final concentration of 50 µM, 
100 µM, 500 µM, and 1 mM when added to cultures at day four.  After 24 hours 
of treatment the cultures were counted as described above and used for cell 
cycle experiments as delineated in the flow cytometry section.  
Polysome Profiling
Cells grown in culture were treated with a 1/100 vol of 9 mg/ml 
cycloheximide  (Sigma) for 10 minutes at 37oC.  All solutions used in harvesting 
polysome samples In subsequent steps also contianed the same concentration 
of cycloheximide.  Cells were trypsinized (0.25% Trypsin EDTA, Invitrogen) when 
appropriate, or pelleted by centrifugation at 800 x g for 5 minutes.   Cells were 
washed with cold PBS (VWR), and lysed using a handheld homogenizer (Fisher) 
in polysome buffer containing 50 mM Tris-HCl pH 7.5 (Fisher BP152-1, prepared 
with DEPC treated water as  a 1M stock solution and titrated to pH 7.5 with 
concentrated HCl), 240 mM NaCl (Fisher S271-1 prepared with DEPC treated 
water as a stock solution of 2 M), 10 mM MgCl2 (Sigma M1028), 5 mM β-
mercaptoethanol (Sigma), 250 mM Sucrose (Fisher BP220-212), 2% Triton X 
(Sigma), 100 µg/ml heparin (Alfa Aesar), and 90 µg/ml cyclohexamide (Sigma-
C7698).  Debris was pelleted in a refrigerated microcentrifuge (Eppendorf) at 
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8000 x g for 10 minutes and the RNA concentration of the supernatant 
determined using a Nanodrop (Thermo Scientific).  Equal quantities of total RNA 
in a maximum volume of 350 µL were added to the top of 15-55% sucrose 
gradients.  Gradients were poured using a bone marrow biopsy needle into 
RNAse/DNAse free round bottom polyallomer 17 mL tubes  (#5042) from Seton 
Scientific with 3 mL layers of 15% (w/v), 25%, 35%, 45%, and 55% sucrose 
(Fisher BP220-212) containing 25 mM pH 7.5 Tris-HCl (Fisher: BP152-1, 
prepared with DEPC treated water as  a 1 M stock solution and titrated to pH 7.5 
with concentrated HCL)  25 mM NaCl (Fisher S271-1 prepared with DEPC 
treated water as a stock solution of 2 M) and 5 mM MgCl2 (Sigma M1028, stock 
solution). Gradients were centrifuged at 28,000 rpm in a SW 28 rotor for 7-12 
hours using a Beckman L8-M ultracentrifuge.  The gradient fractions were then 
collected using an ISCO density gradient fractionator (Model 185), retriever 
(Retriever 500), and flourinert (Sigma) and visualized using a UA-6 UV/Vis 
detector (ISCO), and type 11 optical unit with filters corresponding to 254nm 
(ISCO) (Jaako et al., 2011).  
Western Blotting
Cell pellets were harvested and lysed by snap freezing in RIPA buffer 
containing leupeptin, aprotinin, PMSF, and protease inhibitor cocktail (Sigma).  
Cell debris were pelleted by centrifugation at 5,000 x g in a refrigerated 
microcentrifuge (Eppendorf).  Protein concentration was determined using the 
BCA method (Thermo Fisher) and equal concentrations of protein were 
suspended in Nupage buffer (Invitrogen) containing dithiothreitol ( 50mM DTT; 
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Sigma).  SDS-PAGE was performed using 2.5 µg to 10 µg of protein and 4-12% 
Bis-Tris Ready gels (Invitrogen) with protein size estimated by Biorad dual color 
standards.  After transferring proteins to nitrocellulose membranes (BioRad) in 
transfer buffer containing 20% methanol (Fisher) overnight at a constant 20 Volts 
at 4oC (BioRad transfer apparatus), membranes were blocked with 5% milk in 
TBST (Fisher) and immunoblotting was performed using the following antibodies: 
anti-RPS19 (H00006223-M01, Abnova; 1:1,000), anti-RPL5 (ab74744, Abcam; 
1:500-1:1000), anti-p53 (9282, Cell Signaling; 1:1000-1:2000), anti-RNA 
Polymerase II p.14.5 (abs8436, Abcam; 1:2,000), anti-LDH-A (SC27230, Santa 
Cruz; 1:1,000), anti-VDAC1 (4661, Cell Signaling; 1:1,000), anti-cytochrome c 
(SC-7159 Santa Cruz; 1:1,000), anti-Tom20 (a custom antibodyreceived as a 
generous gift from Dr. Brian Wattenberg1:500), anti-pyruvate dehydrogenase, 
PDH, (SC-65242, Santa Cruz, 1:1,000), anti-superoxide dismutase 2, SOD2, 
mitochondrial (SC-20080, Santa Cruz, 1:1,000), anti-Tom40 (SC-11414, Santa 
Cruz, 1:1,000), anti-isocitrate dehydrogenase 3α, IDH3α, (AP1927a, Abgent, 
1:1,000),  anti-IDH2 (H00003418-A01, Novus biological supplied by Abnova, 
1:1,000), anti-β tubulin (ab6046, Abcam, 1:1,000) and anti-β-actin (SC69879 
AC-15 Santa Cruz; 1:5,000). Secondary antibodies used were either goat anti-
mouse (#3430 Thermo Scientific and Santa Cruz), goat anti-rabbit (7074, Cell 
signaling technology), or donkey anit-goat (SC2020, Santa Cruz) as dictated by 
the primary antibody. The resulting complexes were detected using 
chemiluminescent reagents and protocols from Pierce Chemical, GE Healthcare, 




To analyze the relative amounts of cells in different phases of the cell cycle 
in asychronized cultures, 1×106 TF-1 cells expressing lentiviral vectors targeting 
SBDS mRNA or scrambled controls were harvested and washed with PBS.  Cells 
were fixed in 70% ethanol for at least 30 min at -20o C and washed twice with 
PBS.  After resuspension in 1 ml of PBS, cells were treated with ribonuclease at 
100 µg/ml (RNAse A, Qiagen, MD).  Propidium iodide was added to a final 
concentration of 50 µg/ml (Invitrogen), and samples were analyzed with a BD 
FACS Calibur (BD Biosciences, San Jose, CA) cytometer. The events were gated 
to remove both debris and doublets (signals generated by clumps of two or more 
cells) and 20,00-50,000 total events were used for subsequent analyses.  The 
FL3H-PI channel was used for data collection.  The resulting histograms were 
analyzed using FlowJo software and the Dean/Jett/Fox method used to quantify 
phases of the cell cycle (Treestar Ashland, OR) (Dempster A, 1977; Fox, 1980; 
Krishan, 1975; S, 1997; Shapiro, 2003; Watson et al., 1987; Webb, 2002). 
JC-1 Mitochondrial Membrane Potential Assay 
Mitochondrial membrane potential was assessed using the JC-1 Assay kit 
from Molecular Probes according to the manufacturer’s instructions.   This assay 
measures mitochondrial membrane potential irrespective of mitochondrial size or 
density.  The JC-1 compound ((5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimi-
dazolylcarbocyanine iodide) shows a shift in emission spectrum from green  (529 
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nm) when the dye is outside of mitochondria to red (590 nm) as the dye enters 
mitochondria in a membrane potential-dependent manner and forms aggregates 
that are no longer able to leave the mitochondria.  Pretreatment with 50 mM 
CCCP, an uncoupler which dissipates the proton gradient, prevents the 
accumulation of JC-1 in mitochondria and served as a negative control. 
Unstained cells served as a control for cellular autofluorescence.  After 
incubation with the JC-1 compound for 20 minutes at 37oC, cells were harvested 
and suspended in PBS for analysis with a BD FACS Calibur (BD Biosciences) 
cytometer.  A dot plot of side scatter (SSC) and forward scatter (FSC) was used 
to determine the gating of the appropriate population of live cells and to remove 
debris.  At this point any extracellular JC-1 that wasn’t removed as cells were 
harvested and washed was also eliminated.  
The following strategy was employed to analyze the membrane potential 
data generated by flow cytometry.  The FL2 channel was used to measure red 
fluorescence and is graphically represented on the y-axis and the FL-1 channel 
was used to measure green fluorescence which is graphed on the x-axis.  
Quadrants were created in the plot to capture different cell populations.  The 
lower left quadrant represents auto-fluorescence and was defined by unstained 
control samples.  The upper right quadrant includes cells expressing high levels 
of green and red fluorescence and represents the mitochondrial potential of 
control TF-1 cells.  The lower right quadrant represents cells with relatively high 
green fluorescence but low red fluorescence as would be expected if the 
membrane potential was decreased (Chaoui et al., 2006; Chazotte, 2011; 
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Cossarizza and Salvioli, 2001; Garner and Thomas, 1999; Guthrie and Welch, 
2008; Keil et al., 2011; Legrand et al., 2001; Lugli et al., 2007; Reers et al., 1995; 
Salvioli et al., 1997; Simeonova et al., 2004; Smiley et al., 1991).  A minimum of 
40,000 events were collected for each sample replicate.  Analyses were 
performed using FlowJo software from Treestar to perform appropriate 
compensation, gating, and comparison of all replicate data using the same 
parameters.  
Annexin V/ Propidium Iodide Assay of Apoptosis 
Flow cytometry was also employed to study apoptosis in our cell lines.   
Cells were stained with annexin and propidium iodide (PI) prior to evaluation by 
flow cytometry.  An Annexin V-FITC/PI kit was purchased from E-Biosciences and 
experiments performed according to the manufacturer’s instructions.  The 
annexin V stain recognizes outer membrane phosphatidylserine molecules 
whose hydrophilic head flips from the inner to the outer membrane during early 
phases of apoptosis. Co-staining with PI allows one to exclude cells from the 
analysis whose membranes are no longer intact, as PI stains the DNA/RNA 
species of necrotic cells or those in the later stages of apoptosis. The samples 
were analyzed using the BD FACS Calibur (BD Biosciences) with a minimum of 
40,000 events collected. The samples were gated using an unstained control 
sample as well as single-stained controls treated with only PI or annexin-V.  The 
data collected were then analyzed using FlowJo software (Treestar).  Data were 
plotted with FL3-PI on the Y-axis and FL1-H: annexin V on the X axis.  As before, 
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the lower left quadrant represents autofluorescence, as was delineated using 
unstained control samples.  Cells staining highly for both PI and Annexin-V were 
then found in the top right corner.  These samples were labeled as “late 
apoptosis.”  Those samples contained in the lower right corner, staining highly for 
Annexin-V only were considered “early apoptotic” cells.  The percentage of 
events contained within each of the quadrants was then calculated.  
Reactive oxygen species
 Reactive oxygen species were measured using 2',7'-dichlorfluorescein-
diacetate (DCFH-DA).  DCFH-DA is rapidly converted to the non-fluorescent 
compound DCFH once inside cells by cellular esterases.  In the presence of 
ROS cellular peroxidases convert DCFH to DCF which is highly fluorescent.  
Measurement of DCF fluorescence thereby provides a measure of cellular ROS.  
This assay for detecting ROS was modified from previously published work 
(Ambekar et al., 2010).  Viable TF-1 cells were counted using Trypan blue 
exclusion and plated in 96 well plates (Costar) at a density of 1x105 cells/well.  A 
minimum of three replicates was used for each sample including control treated 
with DMSO and CCCP.  DCFH-DA (Sigma) suspended in DMSO (Sigma) was 
added to wells to a final concentration of 20 µM.  After incubation at 37o  for 15 
minutes the plates were then read once every minute using filters appropriate for 
an excitation wavelength of 505 nm and emission at 529 nm using the Synergy 
plate reader (Biotek).  After subtracting the intensity of the blank (DMSO), values 
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for three replicate experiments are represented as a ratio of fluorescence 
intensity with SBDS knockdown relative to scrambled controls. 
Oxygen consumption
 Oxygen consumption was measured using a Gilson oxygraph with a 
Clark-type electrode following previously published protocols (Campian et al., 
2007; Gao et al., 2010).  Cells were suspended in 550 µl of growth media at a 
concentration of 2.7 x 106 cells/ml and placed in the chamber.  Basal respiration 
tracings of oxygen consumption were monitored for two minutes.  Carbonyl 
cyanide m-chlorophenyl hydrazine, CCCP (Sigma), was added to the chamber 
using a Hamilton Syringe to a final concentration of 10 mM to measure maximal 
respiration rates of each sample for eight additional minutes.  Respiration rates 
were expressed as µmol of oxygen consumed per million cells per minute.  
Linear portions of the curves were then used to express respiration rates in terms 
of the basal respiration rate relative to the maximal respiration rate. 
Statistical Analysis
 All data are presented as the result of no less than three independent 
experiments.  Microsoft’s Excel program and Graphpad’s Prism software were 
used to perform all statistical analyses of replicate data.  When appropriate an 
unpaired Student’s t-test was used to determine the significance of differences 
between sample means.  ANOVA statistical analyses were run when indicated by 
sample demographics and the appropriate post-hoc tests used based on sample 
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parameters.  Unless otherwise stated, bar graphs represent the mean of all 
experimental replicates using the standard deviation for error bars and asterisks 
represent p-values as such:  *p<0.05, **p<0.01, ***p<0.005.
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CHAPTER III
THE VITAL ROLE OF PRE-RRNA PROCESSING IN DBA DIAGNOSIS 
AND GENE DISCOVERY
Introduction
 Diamond Blackfan Anemia, (DBA), was first linked to a mutation in the 
gene encoding a ribosomal protein, RPS19, in 1999.  Since then, causative 
mutations have been indentified in 10 genes that encode protein components of 
both small and large ribosomal subunits (Ball, 2011; Draptchinskaia et al., 1999).  
Despite this progress, the genes affected in many patients have not been 
identified using DNA sequence analysis of candidate ribosomal protein genes.  
Current genome-wide efforts have been able to identify patients with large 
deletions including known ribosomal protein genes that were not picked up by 
DNA sequencing.  Still, the underlying genetic defect is still unknown in 
approximately 40% of DBA patients (Boria et al., 2010; Farrar et al., 2011). 
 Pre-rRNA processing experiments have played a critical role in gene 
discovery efforts in DBA, linking mutations in prospective genes to defects in 
ribosome synthesis (Campagnoli et al., 2008; Choesmel et al., 2008; Farrar et 
al., 2008; Flygare et al., 2007; Robledo et al., 2008; Rouquette et al., 2005).  The 
role of pre-rRNA processing in gene discovery has become even more critical as 
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whole genome approaches have been applied to identifying new DBA genes 
whose potential role in ribosome synthesis is potentially more tenuous than that 
for ribosomal protein genes.  The work described in this chapter illustrates the 
contribution pre-RNA processing studies can make to diagnosing DBA in 
challenging clinical cases and in discovering new genes beginning with the 
description of a particularly challenging case.  An outgrowth of these studies is 
the identification of a new strategy for tracking pre-rRNA processing defects 
associated with genes encoding large subunit ribosomal proteins.  We feel that it 
should be possible for clinical laboratories to develop this approach as a new 
diagnostic tool for DBA.  Finally, these studies highlight ribosomal proteins RPL5 
and RPL11 as playing a unique role in DBA pathophysiology based on their 
interaction with 5S rRNA and the distinctive role of the RPL5/RPL11/5S rRNA 
complex both in ribosome biogenesis and signaling ribosome stress.    
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Case Report 
 A child presented to a physician in the San Diego area at four months of 
age with a severe macrocytic anemia.  She also had neutropenia and elevated 
numbers of morphologically normal platelets, which does not fit the classical 
criteria for DBA.  She could however potentially fall under a broader diagnostic 
heading of non-classical DNA.  Non-classical DBA includes patients exhibiting 
effects on myeloid lineages other than erythrocytes (Boria et al., 2010; Farrar et 
al., 2011; Vlachos et al., 2008).  In addition to her hematopathology, the proband 
had multiple congenital anomalies including bilateral fusion of the radius and 
ulna.  Both of her thumbs showed aberrations in development that were not 
symmetrical.  One hand contained a triphalangeal thumb and the other was 
hypoplastic.  Bone marrow biopsy revealed a paucity of erythroid precursors and 
a block in maturation of granulocyte precursors that would normally differentiate 
into neutrophils, and a normal female (46XX) karyotype.  Given the lack of a 
clear diagnosis based on the patient’s clinical profile, molecular studies analyzing 
the possible involvement of multiple inherited bone marrow failure syndromes 
(IBMFS) were performed. 
 The litany of laboratory tests that ensued began with analyses of defects 
associated with the most common IBMFS, Fanconi Anemia (FA) (Shimamura and 
Alter, 2010).  Fanconi anemia results from defects in DNA repair and patient 
lymphoblasts were tested for their sensitivity to DNA crosslinking agents, a 
routine test for this disease (Shimamura and Alter, 2010).  These tests were 
negative. Shwachman Diamond syndrome was also considered unlikely as no 
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pathogenic mutations were found in the SBDS gene, which is affected in over 
90% of SDS patients (Dror and Freedman, 1999, 2002; Johnson and Ellis, 2011; 
Nihrane et al., 2009; Tsangaris et al., 2011; Yamaguchi et al., 2011).  Tests were 
also performed on the eleven ribosomal protein genes known to be involved in 
DBA.  While two single nucleotide polymorphisms were found, one each in 
RPS19 and RPL11, these changes were unlikely to be deleterious.  
Our collaborators then turned to comparative genomic hybridization 
(CGH), a technique for scanning the entire genome for copy number variations.  
CGH on this patient revealed a 3.2 megabase deletion on chromosome 2 at 
2q11.2. This result was confirmed by fluorescence in situ hybridization.  Further, 
as neither parent exhibited this deletion it was presumed to have arisen 
spontaneously in the child.  The deletion at 2q11.2 observed in this child includes 
a number of genes including RPL31, which encodes a ribosomal protein of the 
60S subunit.  This suggested the child could be haploinsufficient for RPL31, 
which would be consistent with a diagnosis of Diamond Blackfan anemia.  
However, as RPL31 has not been identified as a DBA gene previously, we felt it 
was important to address whether the 2q11.2 deletion was associated with a 
defect in ribosome biogenesis in this patient.   
 To address whether this child had a defect in ribosome biogenesis, we 
employed a protocol we recently developed as part of a consortium of 
investigators studying the molecular basis of DBA.  This protocol involves the 
isolation of mononuclear cells from peripheral blood, followed by culturing and 
activating T lymphocytes with concanavalin A (ConA) (Farrar et al., 2011).  Total 
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RNA isolated from these cells is then used for pre-rRNA processing studies.  This  
technique has so far revealed robust and reproducible pre-rRNA processing 
defects in many DBA patients.  
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Results 
Pre-rRNA processing defects associated with haploinsufficiency for RPL31
 Fig. 5A shows an ethidium bromide stained RNA samples in a 
formaldehdye gel of samples obtained from the index proband from San Diego.  
The samples were sent to us blinded, and the codes revealed only after pre-
RNA processing studies were completed and data analyzed.  Samples included 
the proband, her unaffected parents, and an unrelated healthy control.  Even at 
the level of ethidium bromide visualization with UV, it was clear one of the four 
samples stood out from the others.   Sample 06518 has a prominent band above 
that of 28S rRNA, later shown by hybridization to be 32S pre-rRNA (Fig. 5B and 
Fig 6).  Subsequent decoding of the samples revealed that 06518, was in fact 
derived from the proband.  As shown in Fig. 1, 32S pre-rRNA contains both 5.8S 
and 28S mature RNAs separated by an intervening sequence labeled ITS2.  
Cleavages within ITS2 ultimately give rise to the 3′ end of 5.8S RNA and the 5′ 
end of 28S RNA.  The pre-RNA processing defect in this sample is specific for 
RNA components of the large subunit as would be expected for RPL31, a large 
subunit ribosomal protein. 
 63
 
Fig 5: Pre-rRNA processing defect associated with haploinsufficiency for 
RPL31
Total RNA from blood mononuclear cells cultured for 96 hours in the presence of 
ConA was isolated and separated on 1.5% formaldehyde agarose gels.  Sample 
codes and RPL31 gene status are listed below each duplicated sample. (A) RNA 
gel of ethidium bromide stained samples (B) RNA was transferred to zeta-probe 
and hybridized with probe ITS2b (Sequence in Table 1).  The pre-rRNA labeled 
32S pre-rRNA was confirmed using a number of different oligonucleotides for 
hybridization to demarcate its boundaries in both this gel (Fig 6) and in a gel with 
other DBA patient samples shown in Fig 7 and 8. 
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Fig 6: Northern blot of RNA isolated from the index proband, unaffected 
parents, and a healthy control reveals a processing defect in proband pre-
rRNA 
(A) Northern blot of the gel shown in Fig. 5  after probing with an oligonucleotide 
complementary to sequences bridging the 3′ end of 5.8S rRNA and the 5′ end of 
ITS2.  (B) The membrane in A was stripped and probed with an oligonucleotide 
complementary to mature 5.8S rRNA.  The pre-rRNA and rRNA species are 
labeled to the right of the northern blots and the patient number and genotype 
shown below.  All samples were run in duplicate.  
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A common pre-rRNA processing signature in patients haploinsufficient for large 
subunit ribosomal proteins
 To compare the pre-RNA processing defect associated with RPL31 
haploinsufficiency with that for haploinsufficiency of other large subunit ribosomal 
proteins, we analyzed samples from patients with mutations in either RPL5 or 
RPL35A, two known DBA genes encoding large subunit proteins (Farrar et al., 
2008; Gazda et al., 2008).  Fig. 7A shows an ethidium bromide-stained gel of the 
different patient samples together with an unaffected parent of the RPL31 patient. 
Here again, a prominent band just above the 28S rRNA is evident in the patient 
samples, but is present in much lower amounts in the healthy controls.  Fig. 7B 
shows this band is 32S pre-rRNA.  Thus, it would appear from each of the DBA 
samples we have tested where a large subunit ribosomal protein gene is 
responsible for the disease, there is a clear increase in 32S pre-RNA evident at 
the level of ethidium bromide staining.  A similar sized band has been observed 
in RNA gels of patients with mutations in RPL11 (Elisa Pavesi, University Eastern 
Piemonte, Novara Italy, personal communication) indicating that an increase in 
32S pre-rRNA may be a common characteristic of deficiencies of large subunit 
ribosomal proteins.  Given that this increase can be visualized by gel 
electrophoresis and ethidium bromide staining, the increase in 32S pre-rRNA 
may be developed as a diagnostic tool for DBA when genes encoding large 
subunit ribosomal proteins are suspected.
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Fig 7: Evidence of a common pre-rRNA processing signature associated 
with haploinsufficiency for large subunit ribosomal proteins.
(A) Total RNA was prepared from peripheral mononuclear cells cultured for 96 
hours in the presence of ConA.  RNA was fractionated on 1.5% formaldehyde 
agarose gels and stained with ethidium bromide.  Affected genes in patient 
samples are listed above each lane.  When a gene is listed twice this denotes 
duplicated samples from the same patient.  The healthy control is denoted as Wt.  
(B) RNA was transferred to a zeta-probe membrane and hybridized with 
oligonucleotide “ITS2b” which is complementary to sequences within ITS2 
(sequences shown Table 1).  
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5S RNA is selectively decreased in cells haploinsufficient for RPL5
 To determine if we could identify unique pre-rRNA processing 
characteristics associated with any of the large subunit protein genes studied 
here, we analyzed the membrane above (Fig. 7) using additional probes.  The 
most striking difference between the pre-rRNA processing patterns for the 
affected genes is the decrease in 5S rRNA observed in the cells derived from a 
patient with mutated RPL5 (Fig. 8B).  The decrease is selective for 5S RNA as 
there is little change in 5.8S RNA in the RPL5 sample compared to the others 
(Fig. 8C).  Thus, it may be possible to further refine the diagnostic power of pre-
rRNA processing to identify signatures associated with specific ribosomal protein 
gene mutations.   
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Fig 8: Northern Blots of DBA patient samples reveal a unique processing 
signature in a patient where RPL5 is mutated.  
Total RNA from stimulated blood mononuclear cells was transferred to zeta probe 
membrane and hybridized with probes listed in Table 1.  Names of probes used 
in the labeling of the Northern blots are shown at the top of each panel.  The 
gene mutated in each sample is listed above each lane, with the healthy control 
samples listed as Wt.  
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The 5S RNA subcomplex as a possible mediator of ribosome stress signaling
 The decrease in 5S rRNA in samples from patient’s haploinsufficient for 
RPL5 has a number of implications for DBA pathophysiology.  The 5S RNA is 
unique among the four rRNA species found in eukaryotic cytoplasmic ribosomes.  
It is the only rRNA transcribed independently by RNA polymerase III, as opposed 
to the other three rRNAs transcribed together by RNA polymerase I (Allison et al., 
1995; Ciganda and Williams, 2011; Zhang et al., 2007).  This unusual 
organization lends itself to the potential adaptation of 5S RNA and its associated 
proteins, RPL5 and RPL11, as a novel signaling subcomplex of the ribosome.  In 
fact, many studies have suggested that ribosome stress is mediated through the 
interactions of RPL5 and RPL11 with MDM2, which results in stabilization and 
activation of p53 (Honda et al., 1997; Kubbutat et al., 1997).  Additional work has 
implied that 5S rRNA is involved in this process by forming a stable subcomplex 
with RPL5 and RPL11 and that it is the subcomplex that actually interacts with 
MDM2 in vivo  as shown by the synergistic inhibition of MDM2 activity (Allison et 
al., 1995; Fumagalli et al., 2009; Horn and Vousden, 2008; Lipton and Ellis, 
2010).
 While the view that this ternary complex may be free to interact with 
MDM2 when large subunit assembly is disrupted by haploinsufficiency for any 
large subunit ribosomal protein other than RPL5 and RPL11 themselves, it is less 
clear why this complex may be freed to interact with MDM2 when small subunit 
assembly is affected.  Therefore, we were interested in whether there may be an 
increase in free 5S RNA in samples where 40S subunit assembly is disrupted by 
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reduced expression of RPS19.   To address this question, we turned to human 
TF-1 cells where RPS19 expression can be regulated by an inducible shRNA to 
RPS19 mRNA (Flygare et al., 2007).  Fig. 9 shows polysome profiles from cells 
depleted of RPS19 and scrambled controls.  Cells depleted of RPS19 show a 
decrease in free 40S subunits, an increase in free 60S subunits, and a shift from 
larger to smaller polysomes.  This is the expected outcome for a small subunit 
biogenesis defect.  When 40S subunits are limiting, both 40S and 80S species 
are decreased whereas free 60S subunits increase since 40S pre-initiation 
complexes are no longer available.  To monitor the fate of 5S rRNA  under these 
conditions, RNA was precipitated from the polysome fractions of these samples 
and then used for Northern blotting.  Interestingly, the fraction of 5S rRNA in the 
free pool found at the top of the gradient is increased approximately 3-fold from 
~5 to 15% in cells depleted of RPS19 relative to control samples.  While not 
conclusive, these data suggest that increases in the 5S RNA subcomplex may 
occur in cells depleted of RPS19, and in doing so be available for signaling 
ribosome stress to regulators of p53.   
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Figure 9: Polysome profiles of TF-1 samples depleted of RPS19 show an 
increase in the free pool of 5S rRNA. 
TF-1 B and TF-1 SCR cells were treated with doxycycline for seven days to 
stimulate expression of shRNAs targeting RPS19 (TF1-B) shown in (B) or a 
scrambled control sequence (TF1-SCR) shown in (A). The resulting extracts 
were prepared in the presence of cycloheximide and separated by 
ultracentrifugation on sucrose gradients.  Each panel shows representative 
absorbance tracings at 254nm and Northern blots of gradient fractions probed 
with oligonucleotides complementary to either 5S or 5.8S rRNA are shown below. 
Panel C shows the fraction of 5S rRNA found at the top of each gradient relative 
to the total amount of 5S rRNA across the gradients.  Values for the amount of 
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5S rRNA in each fraction were obtained by phosphorimage analysis using 
Imagequant (GE).  Free 5S was determined by adding the band intensities of 
lanes delineated “Free 5S” above the Northern blots over the sum of the 5S 
rRNA signals.  Free 5.8S rRNA was quantified in a similar manner (data not 
shown), but with equivalent results in both control and knockdown samples. Error 
bars represent S.D. with n= 4 and a *p<0.05 value as determined by an unpaired 
student’s t-test.  
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The amount of free 5S RNA in cells depleted of Rps19 was also 
investigated in a different model system of mouse embryonic stem cell lines 
(mES) where a single copy of the Rps19 gene is interrupted by insertion of a 
genetrap retroviral construct between exons 3 and 4.  This leads to a truncated 
mRNA transcript as outlined in the materials and methods chapter.  The gene-
trapped embryonic stem cells were purchased from the Mutant Mouse Regional 
Resource Centers, MMRRC. The system was chosen by one of our collaborators 
to investigate the effects of heterozygosity for Rps19 on different aspects of 
mouse development in in vitro differentiation assays (see appendix).  Extracts 
from the Rps19 gene trap and parental controls labeled YHC and E14, 
respectively were treated as described above for TF-1 cultures and analyzed in 
the same manner.  The results showed the free pool of 5S rRNA increased from 
18% to 25% in the Rps19 gene trap samples relative to control (Fig. 10).  Though 
not as striking a result as those found in the TF-1 model, ribosome defects in 
mouse models are often less severe then those in human cell lines (Flygare et 
al., 2007; Flygare et al., 2005; Gazda et al., 2004; Jaako et al., 2011).   In 
contrast, mES models that recapitulate Rpl5 heterozygosity displayed essentially 
no change in the free pool of 5SrRNA (Fig. 11). 
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Fig 10:  Free 5S rRNA is increased in mouse embryonic stem cells 
heterozygous for Rps19   
RNA was precipitated from polysome fractions of YHC (Rps19 mutant) and their 
corresponding parental control (E14) mES lines.  Northern blots of the RNA 
samples are shown in the top panels and the band intensity quantified in the 
lower panel’s table using Imagequant (GE).  Percentages of rRNA samples in 
each category were calculated by adding the band intensity of each of the lanes 
in the same category and dividing by the total band intensity.  
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Fig 11: Free 5S rRNA is unchanged in mouse embryonic stem cells 
heterozygous for Rpl5  
RNA was precipitated from polysome fractions of D050 (Rpl5 mutant) mES and 
their corresponding parental control (YHC).  Northern blots of the RNA samples 
are shown in the top panels with the quantification performed using Imagequant 
software (GE Healthcare) below.  The amount of 5S rRNA in the first six lanes 
were classified as the free pool, whereas that in lanes from 60S through the  
polysome fractions were considered 60S associated as localized by the 
cosedimintation of 5.8S rRNA.  The Table shows the relative amount of 5S rRNA 
found in each fraction.     
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The 5S rRNA released with abortive assembly in our mES model of small 
subunit protein mutations is presumably free to interact with MDM2 (in 
association with Rpl5 and Rpl11) to prevent MDM2 mediated degradation of p53.  
In the case of the Rpl5 mES model, there is no corresponding increase in 5S 
rRNA in the free pool.  Nevertheless, there appears to be an increase in p53 
protein expression in each of the gene trap cell lines (Fig. 12).  In the S17 
derived Rps19 mutant cell lines, this increase in p53 protein expression is 
evident in the undifferentiated mES cells (Fig. 12A). After stimulation to form 
embryoid bodies, as described in the supplemental section for use as a model of 
primitive hematopoiesis (Fig S4). The YHC Rps19 cell model, as well as the Rpl5 
model, D050, shows an increase in p53 protein expression. These results are 
consistent with a model where p53 activation in cells haploinsufficient for Rpl5 
occurs through a mechanism distinct from that of other ribosomal protein genes, 
excluding Rpl11.     
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Fig 12:  Cells heterozygous for either Rps19 or Rpl5 show an increase in 
p53 expression relative to controls.  
(A) Duplicate samples of control (ORF-17) or Rps19 gene trap (EMT-S17) mES 
cells whole cell lysates were used for SDS-PAGE.  Anti-sera for p53, β-Actin, and 
Rps19 were used for the western blots.   (B) Rpl5 or Rps19 gene trap mES cells 
were differentiated into embryoid bodies and then harvested and whole cell 
lysates used for western blotting using anti-sera for p53, β-Actin, and Rps19.  (C) 
Band intensities of western blots were quantified using ImageJ.  Data in the bar 
graph represent the means of multiple exposures of multiple experimental 
replicates, error bars = S.D., *p<0.05 as determined by unpaired Student’s t-test.  
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Discussion 
 The case reported here illustrates some of the complexities associated 
with making a definitive diagnosis of an inherited bone marrow failure syndrome.  
The child presented with anemia and neutropenia with congenital anomalies 
characteristic of both Diamond Blackfan anemia and Fanconi anemia.  The 
neutropenia could also suggest Shwachman Diamond syndrome (Shimamura 
and Alter, 2010).  Fanconi anemia was ruled out, as the child’s cells did not 
appear to be unusually sensitive to DNA crosslinking agents as would be 
expected for this disease (Shimamura and Alter, 2010). This sensitivity stems 
from the fact that the underlying molecular defect in FA resides in DNA repair at 
sites of double strand breaks (Soulier, 2011).   Sequencing the SBDS gene and 
the 10 known pathogenic ribosomal protein genes associated with DBA in this 
child also revealed no obvious mutations, further complicating the potential of an 
accurate diagnosis.  
 The finding that this child had a 2.3 megabase deletion including the gene 
encoding ribosomal protein RPL31 suggested that she might indeed have DBA 
resulting from ribosomal protein haploinsufficiency.  If confirmed, these studies 
would identify RPL31 as a new DBA gene.  Demonstration of a ribosome 
biogenesis defect can help add to a DBA diagnosis, but analyses such as 
Northern blotting and polysome profiling are restricted to a few research 
laboratories and are unlikely to be adopted in clinical laboratories.  This is, in 
part, due to the complicated equipment used to generate polysome profiles and 
the personnel hazards associated with the radiation used in common Northern 
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blotting techniques.  Having a facile assay that does not involve radioisotopes 
would greatly improve the prospects of monitoring for defects in ribosome 
synthesis as a diagnostic tool for DBA.  
 The data reported here clearly demonstrate that the proband in the index 
case has a pre-RNA processing pattern indicative of a defect in the maturation of 
the 60S subunit as would be expected for haploinsufficiency for a large subunit 
ribosomal protein.  These results strongly support a diagnosis of DBA for this 
patient and also identify RPL31 as a new DBA gene (Campagnoli et al., 2008; 
Choesmel et al., 2007; Farrar et al., 2008; Gazda et al., 2008; Jaako et al., 2011; 
Robledo et al., 2008; Rouquette et al., 2005).  
 The studies reported here also show that patients with mutations in genes 
encoding large subunit ribosomal proteins have a common pre-rRNA processing 
defect visualized at the level of an ethidium bromide-stained gel.  We strongly 
feel that this observation could be readily adapted to a routine assay for patients 
with defects in 60S subunit assembly, which could aide in DBA diagnosis and 
gene discovery efforts.  This assay could be performed in a gel format as 
reported here, or could be readily adapted to testing in a Bioanalyzer, commonly 
used to test RNA integrity prior to quantitative PCR techniques. 
 An additional outcome of our investigation of pre-rRNA processing 
patterns in DBA patients with mutations in large subunit ribosomal protein genes 
was the demonstration that mature 5S rRNA is dramatically and selectively 
decreased in patients haploinsufficient for RPL5.  RPL5 has been known for 
many years to bind directly to 5S rRNA (Allison et al., 1995; Thomas and Kutay, 
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2003).  Work in recent years has shown that RPL11 and two additional ribosome 
associated proteins are required for the incorporation of the 5S subcomplex into 
assembling 60S subunits (Ciganda and Williams, 2011; Dai et al.; Grandi et al., 
2002; Hadjiolova et al., 1993; Horn and Vousden, 2008; Kubbutat et al., 1997; 
Lohrum et al., 2000; Lohrum et al., 2003; Zhang et al., 2007).  
 In addition to its role as a vital component of the 60S subunit, increasing 
data suggest that this subcomplex also plays a critical role in ribosomal stress 
signaling.  The complex of 5S rRNA together with RPL5 and RPL11 has been 
shown to bind to the ubiquitin ligase MDM2 and inhibit its activity toward p53 
resulting in an increase in the amount and activity of p53 (Dai et al., 2007a; Dai 
and Lu, 2004; Dai et al., 2007b; Dai et al., 2006; Dai et al.; Dai et al., 2004; 
Montanaro et al., 2007; Sun et al., 2007).    This ribosome stress signaling 
pathway has been reported in several studies to play an important role in the pro-
apoptotic phenotype of erythroid precursors in DBA (Badhai et al., 2009; Dai and 
Lu, 2008; Danilova et al., 2008; Horos et al., 2012; Jaako et al., 2011; Kuramitsu 
et al., 2008; Miyake et al., 2008; Ofir-Rosenfeld et al., 2008; Uechi et al., 2008).  
 Consistent with this view, our data indicate that the level of free 5S rRNA 
(presumably in complex with RPL5 and RPL11) increases even in cells where 
small subunit ribosomal proteins are depleted in both a human cell line and in 
mouse embryonic stem cell models of DBA.  Thus, the 5S rRNA subcomplex may 
play a critical role in ribosome stress signaling and thereby an important role in 
the pathophysiology of most cases of DBA.
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 A critical role of the 5S rRNA subcomplex in ribosome stress signaling in 
DBA patients seems at odds with the finding that both RPL5 and RPL11 are DBA 
genes.  Our observation that 5S rRNA is dramatically decreased in patient 
samples from a patient haploinsufficient for RPL5 strongly suggests that the 5S 
rRNA subcomplex would be limiting for 60S subunit formation leaving little 
available for stress signaling. This apparent paradox could be reconciled if there 
were an alternative pathway used to signal ribosome stress in such cells.  Such a 
pathway could dominate in cells where the 5S rRNA subcomplex was unavailable 
such as in patient’s haploinsufficient for RPL5 or RPL11.  Interestingly, this 
alternative pathway may have characteristics distinct from the 5S rRNA 
subcomplex in ribosome stress signaling as DBA patients with mutations in RPL5 
and RPL11 tend to have more severe forms of the disease with a greater 
spectrum of congenital anomalies including cleft lips and palates (Gazda et al., 
2008).  The existence of this alternative pathway in patients with RPL5 mutations 
is supported by the observation that p53 levels increase in the cells without an 
increase in the pool of free 5S rRNA (Fig. 11-12).  
 As the patient reported here is the first to have a mutation in RPL31 it is 
too soon to tell if all of her clinical characteristics stem from the loss of RPL31.  It 
is possible that some of her clinical features may be caused by loss of other 
genes in the deleted region.  As RPL31 will likely now be included for sequence 
analysis in DBA patients lacking mutations in other known genes, it is possible 
that other patients will be identified that only have mutations in this gene.  The 
clinical features of such patients will help resolve this issue.      
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Conclusions and Future Directions
This work identifies RPL31 as a new potential DBA gene and adds to the 
growing list of ribosomal protein genes known to be mutated in this puzzling bone 
marrow failure.  These studies represent the first description of a possible 
diagnostic assay for DBA patients with mutations in large subunit ribosomal 
protein genes based on the visualization of increased 32S pre-rRNA with UV light 
in standard RNA gels.  The straight-forward nature of this assay could lend itself 
to high throughput methods more amenable to a clinical diagnostic laboratory 
such as bioanalyzers routinely used for assaying RNA quality for reverse 
transcription PCR.  
After identification of this patient as a non-classical DBA patient, the child 
and her family, can obtain information, support, and guidance associated with the 
already existing infrastructure of the North American DBA Registry.  Though the 
patient whose samples containing a deletion of RPL31 made this research 
possible died during the course of this study, her family will remain a part of the 
DBA family.  May this research be a celebration of her life!
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CHAPTER IV
 MITOCHONDRIAL DYSFUNCTION IN A HUMAN CELL LINE MODEL OF 
SHWACHMAN DIAMOND SYNDROME
Introduction
Shwachman Diamond syndrome (SDS; OMIM 260400) is one of a class of 
inherited bone marrow failure syndromes (IBMFS).  Its clinical presentation 
typically  includes exocrine pancreatic insufficiency, cartilage disorders, and 
neutropenia, though deficits in multiple blood lineages have been seen in 
patients (Burwick et al., 2011).   Patients with SDS have a greatly increased risk 
for myelodisplastic syndromes (MDS) and acute myelogenous leukemia (AML).  
Some studies estimate up to 40 percent of SDS patients will be affected MDS/
AML by age 30 (Donadieu et al., 2005; Dror and Freedman, 2002; Shimamura 
and Alter, 2010; Smith et al., 1996; Tamary et al., 2010).  Over 90% of SDS 
patients have pathogenic mutations in the gene SBDS (Shwachman Bodian 
Diamond Syndrome) (Boocock et al., 2003).  The majority of mutations are 
located in exon two with many resulting from gene conversion with the adjacent 
pseudogene (Burroughs et al., 2009).  The diverse biological systems affected by 
mutations in SBDS suggest that SBDS may be a multifunctional protein.  SBDS 
is reported to have many functions including ribosome biogenesis (Austin et al., 
84
2005; Finch et al., 2011; Ganapathi et al., 2007; Menne et al., 2007; Moore et al., 
2010; Orelio et al., 2011; Vitiello et al., 2010; Wessels et al., 2006; Wong et al., 
2011), maintenance of bone marrow stromal environment (Leung et al., 2011), 
chemotaxis, mitotic spindle stability (Austin!et!al.,!2008;!Orelio!and!Kuijpers,!2009;!
Orelio!et!al.,!2009) and regulating apoptosis pathways (Ambekar et al., 2010; 
Rujkijyanont et al., 2008; Watanabe et al., 2009).  
 Much of our current knowledge regarding SBDS function in ribosome 
biogenesis was obtained using yeast models lacking SDO1, the yeast ortholog of 
SBDS.  One possible explanation for the multiple functions associated with the 
loss of SBDS in human cells is that some of these properties are a consequence 
of downstream effects of the loss of members of the SBDS protein family on 
translation output.  To address this issue, Dr. Joseph B Moore IV in our laboratory 
analyzed the effect of loss of SDO1 on translation in yeast.  To this end, cells 
were pulse labeled for 30 minutes with [35S]-Met and proteins resolved by two-
dimensional gel electrophoresis.  Fig. 13 shows the results of this analysis. One 
of the proteins shown to be substantially increased in ΔSDO1 cells relative to 
controls was identified as Por1, the yeast ortholog of VDAC1, a voltage 
dependent anion channel of the mitochondrial outer membrane (McDonald et al., 
2009).  This observation led us to the finding that yeast cells lacking Sdo1 were 
incapable of growing on non-fermentable carbon sources indicating that they had 
defective mitochondrial function.  The studies described in this chapter are 
focused on mitochondrial function in a human erythroleukemia cell line depleted 
of SBDS.  The first portion of this chapter will discuss the development and 
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characteristics of a human cell line depleted of the SBDS protein, while the 
remaining studies will focus on testing the hypothesis that mitochondrial function 
may be disrupted in cells depleted of SBDS.  
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Fig 13: Por1 expression is increased in ΔSDO1 yeast strain
Wild-type (left panels) and ΔSDO1 (right panels) strains were incubated for 30 
minutes with [35S]-Methionine.  Total protein extracts were resolved by 2D gel 
electrophoresis.  The pH gradient for IEF was 3-10.  The second dimension was 
resolved via a 4-12% polyacrylamide gel.  Molecular masses for size standards 
are shown to the left.  Regions enclosed by the boxes are expanded above each 




Targeting SBDS gene expression in the human erythroleukemia TF-1 cell line 
Our goal was to create a tissue culture model for Shwachman Diamond 
syndrome by using shRNA technology to reduce expression of SBDS in a human 
cell line.  This approach was necessary given the limited availability of patient 
samples for this rare bone marrow failure syndrome.  SBDS is a multifactorial 
bone marrow failure that has been shown to affect numerous blood cell lineages, 
so the TF-1 erythroleukemic cell line was chosen for its ability to differentiate 
along various myeloid lineages (Dror and Freedman, 1999; Leung et al., 2011; 
Miyake et al., 2005; Rawls et al., 2007; Sen et al., 2011; Wong et al., 2011). 
Steady-state levels of SBDS were monitored in cell lines transduced with 
lentiviral vectors expressing shRNAs to SBDS or scrambled controls.  To this 
end, whole cell extracts were prepared, proteins fractioned by SDS-PAGE, 
transferred to nitrocellulose filters and immunoblotted with anti-sera raised 
against SBDS, or β-actin as a loading control.  Fig. 14A shows that relative to 
scrambled controls the steady-state amount of SBDS was reduced to near 
undetectable levels.  Reduced SBDS expression was also observed at the 
mRNA level as determined by qRT-PCR (Fig. 14B).  SDS is an autosomal 
recessive disease with most patients expressing very low levels of SBDS, 
typically from hypomorphic alleles.  Consequently, only clones expressing SBDS 
at levels below 30% of wild-type were used for subsequent studies.  
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Fig 14: Steady-state amounts of SBDS protein and mRNA in TF-1 clones. 
(B) Immunoblot of whole cell lysates of TF-1 cells transduced with lentiviruses 
expressing shRNAs against SBDS mRNA or scrambled controls. Membranes 
were blotted with anti-sera raised to SBDS or β-actin.  (A) qRT-PCR of SBDS 
mRNA from total RNA isolated from lentiviral transduced TF-1 cells.  Each bar in 
the graph represents a different clone created during the selection process with 
the numbers corresponding to the sequence of the SBDS plasmid used to 
transduce the TF-1 cells. 
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Reduced SBDS expression slows growth rate and affects 60S subunit maturation 
TF-1 cells depleted of SBDS protein have a slower growth rate when 
compared to the scrambled control samples (Fig 15) in congruence with previous  
cell models of SDS (Menne et al., 2007; Moore et al., 2010).  The reduced 
growth rates of human cell line models of SDS have been correlated with 
adverse effects on the maturation of 60S ribosomal subunits and translation.  
This should come as no surprise with loss of a protein that is integral in 60S 
subunit maturation.  The status of the translational machinery in our model 
system was investigated by a technique called polysome profiling.  Extracts 
suitable for polysome profiling were prepared by harvesting cells in the presence 
of cycloheximide, which inhibits the elongation phase of translation and traps 
ribosomes on mRNAs.  Extracts prepared in the presence of cycloheximide were 
then subjected to sucrose gradient centrifugation.  Gradients were fractionated 
and absorbance at 254 nm was monitored.  A representative absorbance tracing 
is shown in (Fig 16) where cells depleted of SBDS exhibit a modest decrease in 
free 60S subunits and 80S subunits.   More importantly, the decreased 
absorbance in the polysome region indicates a defect in the formation of mature 
ribosomes that are actively participating in translation.  
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Fig 15: Cells depleted of SBDS have a reduced growth rate relative to 
scrambled controls. 
 TF-1 cells treated with lentiviral vectors targeting SBDS expression (dashed line) 
or a scrambled control  (solid line), were counted using trypan blue exclusion for 
cell viability.  (n=3, error bars represent S.D.).  
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Fig. 16: Polysome profiles from TF-1 cells depleted of SBDS and a 
scrambled control.  
The above image is a representative absorbance tracing at 254 nm of TF-1 cells 
fractionated by sucrose gradient centrifugation. Black: scrambled control; Red: 
shRNA to SBDS #2. Cells were harvested in the presence of cycloheximide as 
previously described (16).  The absorbance tracing was captured using an ISCO- 
UV/Vis detector UA-6 and ISCO optical unit type II. Samples were normalized 
relative to the trough following the 40S subunit peak. This result was 
recapitulated in four independent experiments. 
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Previous results have demonstrated a role for SBDS in the release of eIF6 
from 60S subunits.  The eIF6 protein associates with pre-60S subunits in the 
nucleolus and plays an important role in transporting pre-60S particles from the 
nucleus to the cytoplasm.  The eIF6 also has anti-subunit association activity 
which prevents 60S subunits from joining with 40S subunits before they are fully 
matured.  The failure to release eIF6 from 60S subunits in the absence of SBDS 
prevents 60S subunits from prematurely binding to 40S subunit during formation 
of the 80S initiation complex (McDonald et al., 2009; Nihrane et al., 2009; 
Rujkijyanont et al., 2008).  To monitor the relative distribution of eIF-6 between 
free and 60S subunit-bound pools, gradient fractions were immunoblotted for the 
presence of eIF6.  Antibodies against RPS19 and RPL5 were used as controls to 
identify peaks for the small and large subunit, respectively (Fig. 17, top panel).  
These data revealed an approximately 20% increase in eIF6 co-sedimenting with 
60S subunits in cells depleted of SBDS. This increase in association with the 60S 
subunit was shown to be reproducible and statistically significant (n=4, p = 0.001 
as determined by an unpaired Student’s t-test).   
! 
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Fig. 17: Distribution of eIF6 in sucrose gradients derived from TF-1 cells 
depleted of SBDS and scrambled controls.   
Top panel: representative immunoblots of proteins precipitated from sucrose 
gradient fractions of TF-1 cells transduced with the Sigma Aldrich SBDS shRNA 
#2 or scrambled (Scr) lentiviral constructs. The fractions on the far left 
correspond to the top of a gradient. Fractions were precipitated with 10% 
trichloroacetic acid, washed, resuspended in SDS sample buffer, and 1/10 of 
each fraction was loaded on a gel for subsequent immunoblotting.  Anti-sera to 
ribosomal proteins RPS19 and RPL5 were used to identify fractions containing 
40S and 60S subunits, respectively.  60S subunits and 80S monosomes were 
not completely resolved in this experiment. The signal intensity in immunoblots 
were quantified using ImageJ software. Data in the bottom panel are plotted as a 
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ratio of eIF6 co-sedimenting with 60S subunits over eIF6 present in remaining 
fractions at the top of the gradient. The percentage of eIF6 co-sedimenting with 
the 60S subunit fraction was increased by about 20% relative to controls in cells 
depleted of SBDS (1.26 in the SBDS #2 samples and 1.04 in the control 
samples, n=4, column= mean, error bars = SEM, **p≤0.01 as determined by an 
unpaired Student’s t-test).
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SDS model exhibits cell cycle delay and maturation defects
Previous work with cellular models of SBDS has shown a delay in cell 
cycle progression (Ambekar et al., 2010; Ball et al., 2009; Wong et al., 2011).  To 
further validate our model, cell cycle progression was analyzed by flow cytometry 
after permeabilizing cells and treating with RNAse and propidium iodide. A small 
but statistically significant delay in cell cycle progression was observed in cells 
depleted of SBDS. This delay is observed as an average increase of cells in G0/
G1 of approximately 6%, with a corresponding decrease in the percentage of 
cells in S phase (Fig. 18).  
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Figure 18: Analysis of cell cycle progression in cells depleted of SBDS and 
scrambled controls.  
Cells depleted of SBDS and scrambled controls were stained with propidium 
iodide and cell cycle phase was monitored by  flow  cytometry in the FL3H-PI 
channel. 
Top panel: The average of six independent experiments with the standard 
deviation used for error bars.  Data were compared by ANOVA, the difference 
between cells present in G0/G1 relative to S was calculated using an appropriate 
post-hoc test as 8%, with **p <  0. 01.  
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Bottom panel: representative histograms with the shaded regions depicting the 
most likely mathematical model as determined by the Dean/Jett/Fox method 
using FlowJo software.  The first peak, containing 2N DNA content represents 
cells in the G0/G1 phase. The peak at the far right  represents cells that have 4N 
DNA content and are in the G2/M phase of the cell cycle. The intermediate cells 
are in the synthesis phase and have varying DNA content. The black outline 
shows the histogram of raw data generated with the mathematical algorithm of 
the Dean/Jett/Fox method calculating the most likely peak representations of the 
three cell populations.   
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The depletion of SBDS in TF-1 cells also gave us an opportunity to 
determine the effect of this depletion on the ability of these cells to differentiate 
along the erythroid and granulocyte lineages.  TF-1 cells can be induced to 
differentiate along the myeloid or erythroid lineages in response to the cytokines 
GM-CSF (granulocyte and macrophage colony stimulating factor) and EPO 
(erythropoietin), respectively.  Differentiation is evaluated by colony formation in 
methylcellulose media.  A cluster is considered a “colony” if it contains 40 or more 
cells and plating density is such that that many cells in a cluster have originated 
from a single progenitor (Miyake et al., 2005).  This is analogous to the bone 
marrow derived hematopoietic stem cells giving rise to committed progenitors 
that form colony forming units (CFUs) and as they commit to a particular lineage, 
in this case burst forming units of the erythroid, or granulocyte lineage, BFU-E 
and GM-CFU respectively.  These cells then continue to grow as clumps derived 
from the same progenitor that divide to form a clone or further differentiate 
(Metcalf, 2007).  The viscous medium provides a matrix for the mutli-potent cells 
to differentiate toward a particular cell lineage based on which cytokines are used 
to stimulate them.   This is a common experimental model used to investigate 
IBMFS that have a delay or block in maturation of specific blood lineages.  Fig. 
19 shows a decrease in the ability of SBDS-depleted TF-1 cells to differentiate 
down both erythroid and granulocyte lineages consistent with defects seen in 
SDS patient samples performed by Dr. Sharon Singh in the laboratory of Dr. 
Johnson Liu (Nihrane et al., 2009; Orelio et al., 2009; Rawls et al., 2007; Sen et 
al., 2011; Yamaguchi et al., 2007).
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Figure 19: Analysis of erythroid and granulocyte differentiation of TF-1 
cells depleted of SBDS or scrambled controls 
TF- 1 cells were differentiated into either myeloid or erythroid colonies using GM-
CSF or EPO in methylcellulose media. The #2-12 SBDS knockdown clone had 
decreased myeloid (A) and erythroid (B) colony formation when compared with 
the scrambled #4 control. Markedly smaller colonies were also seen in the #2-12 
clone (C) and (D) . * p=0.0040 ***p=0.0004.
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Changes in oxygen consumption in SDS model
 Previous results in our laboratory showing that  yeast Δsdo1 strains were 
unable to grow on non-fermentable carbon sources sparked our desire to 
address aspects of mitochondrial function in TF-1 cells depleted of SBDS.  In 
yeast, it was possible to assess mitochondrial function by monitoring growth on 
non-fermentable carbon sources.  Similar experiments cannot be performed in 
human cells.  Consequently, we used a number of alternative strategies to 
assess mitochondrial function in TF-1 cells depleted of SBDS.  
 One of these strategies was to monitor oxygen consumption.  Oxygen 
consumption was monitored using a Gilson type oxygraph with a Clark-type 
electrode (Campian et al., 2007; Gao et al., 2010).  These experiments were 
performed with the equipment and guidance of Dr. John Eaton’s laboratory.  Fig. 
19 shows that cells depleted of SBDS consumed less oxygen compared to 
scrambled controls.  Both basal and maximal rates of oxygen consumption are 
decreased, as evidenced by a difference in slopes between the two tracings in 
Fig. 20A both before and after the addition of the uncoupling agent CCCP.  A 
greater effect on basal respiration is evident when the ratios of basal to maximal 
respiration are taken into consideration in the graphs depicting the averages of 
three independent experiments (Fig 20B).   
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Fig 20: Oxygen consumption by TF-1 cells depleted of SBDS compared 
with scrambled controls.
A. Representative oxygen concentration tracings with time before and after 
addition of 10mM CCCP,  B.  Data from panel A were converted to µmol of 
oxygen consumed per million cells per minute and plotted as ratio of basal over 
maximum oxygen consumption rate.  Averages of three independent experiments 
are shown with error bars showing S.E.M. (*p<0.05 as determined by an 
unpaired Student’s t-test)
 102
Changes in mitochondrial membrane potential and mitochondrial protein 
expression with SBDS knockdown
Oxygen consumption is linked to ATP synthesis in mitochondria through 
the chemiosmotic membrane potential created by protons pumped from the 
mitochondrial matrix to the inner membrane space via electron transport.  Given 
the decrease in oxygen consumption in TF-1 cells depleted of SBDS, we were 
interested in whether this finding could be linked to a decrease in mitochondrial 
membrane potential (Wurm et al., 2011).  The Mitoprobe JC-1 assay was used to 
examine mitochondrial membrane potential in TF-1 cells depleted of SBDS and 
scrambled controls.   Cells treated with the JC-1 dye were analyzed by flow 
cytometry.  The JC-1 dye undergoes a membrane potential dependent shift in 
emission spectrum from green (529 nm) to red (590 nm) as it enters and 
accumulates within the mitochondrial matrix  (Chaoui et al., 2006; Chazotte, 
2011; Cossarizza and Salvioli, 2001; Garner and Thomas, 1999; Guthrie and 
Welch, 2008; Keil et al., 2011; Legrand et al., 2001; Lugli et al., 2007; Reers et 
al., 1995; Salvioli et al., 1997; Simeonova et al., 2004; Smiley et al., 1991). 
Mitochondria with normal membrane potential should be able to retain a 
significant quantity of the dye and stain intensely in the red emission spectrum 
and fluorescence in the green emission spectrum validates the use of 
appropriate concentration of the compound were used in staining.  
 After gating to remove debris and dead cells in a separate plot of side 
scatter (SSC) and forward scatter (FSC) such that these signals were not 
included in the analysis a minimum of 40,000 events were counted in each 
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experimental replicate.  Data were plotted with red fluorescence on the Y axis 
(captured with the FL2H channel) and green on the X axis (captured with the 
FL1H channel). Quadrants were centered such that greater than 97% of the 
unstained control sample was found in the lower left quadrant.  Positive controls 
were created in each replicate by pre-treating cells with CCCP, an electron 
transport chain uncoupler which should cause the mitochondrial membrane 
potential to greatly decrease. These samples were found predominately in the 
lower right quadrant.  Thus, the majority of cells will be located in one of two 
quadrants.  Cells highly fluorescing in both the green and red spectrum, as would 
be expected of cells with normal mitochondrial membrane potential, are found in 
the upper right quadrant and cells with lower membrane potential will be in the 
lower right quadrant because they have more intense fluorescence emissions in 
the green rather than the red emission spectrums corresponding to cells with a 
proportionally higher amount of JC-1 dye in the cytoplasm rather than retained 
inside the mitochondria.  
The bulk of cells in the control population treated with JC-1 are found in 
the upper right quadrant with relatively high red and green staining and so 
represents normal mitochondrial membrane potential for TF-1 cells (Fig. 21A).  
Cells depleted of SBDS show a significantly different staining pattern with a 
significantly decreased level of red fluorescence in the majority of cells (Fig. 
21B).    This shift is consistent with a decrease in mitochondrial membrane 
potential in cells depleted of SBDS.  Three independent experiments were 
analyzed to determine relative fractions of normal mitochondria (based on their 
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location in the upper right quadrant) in cell depleted of SBDS relative to controls. 
The results from these analyses are shown in Fig. 21C.  On average 72.8 +/- 3 % 
of scrambled samples were found in the upper right quadrant representing TF-1 
cells classified as having normal mitochondrial membrane potential.  In contrast, 
57.5% +/- 2% of SBDS knockdown cells were found in this quadrant with a 
corresponding shift to the lower right quadrant representing cells with decreased 
mitochondrial membrane potential (Fig. 21, n=12-14 and range = S.E.M., p value 
< 0.001 as determined by Student’s two-tailed t-test).  A Fisher’s exact test to 
assess whether the use of Student’s t-test was appropriate for these analyses 
found the variance between the two means to lack significance, making the 
Student’s t-test an appropriate choice for statistical analysis.  When individual 
clones were compared using one-way repeated measures ANOVA, the means 
between different clones were also found to be statistically significant and a 
Dunnett’s multiple comparison post-hoc test with p values all less than 0.01.  
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Fig 21: Analysis of mitochondrial membrane potential in cells depleted of 
SBDS and scrambled controls 
Flow cytometric analysis of cells treated with JC-1, a cationic dye that 
accumulates in mitochondria in a membrane potential-dependent manner.  The 
JC-1 dye undergoes a fluorescence emission shift from green (529 nm) to red 
(590 nm) upon entry into mitochondria.  Representative histograms are shown 
where FL2-H: JC-1 red fluorescence is plotted on the y-axis and FL1-H: JC-1 
green fluorescence on the x-axis.   (A) scrambled control TF-1 cells treated with 
JC-1 (B) TF-1 cells depleted of SBDS treated with JC-1.  Samples were analyzed 
using FlowJo software as outlined in the Materials and Methods section.  Data 
are plotted as a contour map with cell densities denoted by color and peaks 
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evident by decreased separation between contour lines.  (C) Replicate data from 
three independent experiments are plotted as the percentage of TF-1 cells 
containing normal mitochondria as delineated by the upper right quadrant.  Error 
bars represent S.E.M. (n=3, ***p<0.001 as determined by an unpaired Student’s 
t-test) 
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The data presented thus far indicate that cells depleted of SBDS have 
reduced oxygen consumption and reduced mitochondrial membrane potential.  
This decrease in mitochondrial function could arise from decreased mitochondrial 
mass within the cell or be the consequence organelles with reduced function. To 
assess levels of total mitochondria between cells depleted of SBDS and 
scrambled controls, we examined the expression of a number of mitochondrial 
proteins found in various locations within the organelle (see Table 2 for proteins 
examined).  Unfortunately, no consistent patterns of expression were found in 
this analysis.  Tom20 and Tom40 represent components of the mitochondrial 
import machinery and might be classified as more or less constitutive 
components of the organelle. Despite being part of the same complex, the 
amount of Tom40 increased in cells depleted of SBDS relative to controls 
whereas the level of Tom20 went down (Fig. 22).  Similarly, SOD2 and IDH2, two 
enzymes involved in reducing oxidative stress, also revealed discordant 
responses with SOD2 showing decreased expression with IDH2 increasing (see 
Fig. 21 for representative data). Interestingly, two enzymes involved in energy 
metabolism, pyruvate dehydrogenase (PDH) and isocitrate dehydrogenase, both 
decreased in expression.  The same is true for cytochrome c which plays an 
important role in energy metabolism as a component of the electron transport 
chain.  Finally, the expression of VDAC1 went up in cells depleted of SBDS 
consistent with the results in yeast, where Por1, the yeast ortholog of VDAC1, 
was increased in cells depleted of Sdo1 (Fig 23). 
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Protein Location Function Expression change
Tom20    OMM
Portion of import channel that 
Forms the  receptor site with Tom22 of 
the major mitochondrial protein 
importer. (TOMM)
!
Tom 40    OMM Forms the channel portion of the TOMM import complex   "
VDAC1    OMM Voltage!dependent!ion!channel! "
SOD 2    MM
Mitochondrial specific neutralizer of 
super oxide from electron transport 
chain
!
PDH    MM Decarboxylates pyruvate to form acetyl-CoA, a TCA cycle substrate. !
IDH2    MM
 NADP(+) dependent, catalyzes the 
formation of α-ketoglutarate from 
isocitrate
"
IDH3α    MM
TCA cycle enzyme 
NAD(+) dependent, catalyzes the 
formation of α-ketoglutarate from 
isocitrate
!
Cytochrome C    IM
Loosely associates with the IMM in the 
IM.  Serves was a carrier of electrons 
from Complex III to Complex IV of the 
electron transport chain
!
Table 2: Mitochondrial proteins analyzed using immunoblotting
Mitochondrial proteins, their locations, functions, and relative changes in 
expression between cells depleted of SBDS and scrambled controls are shown. 
Changes in expression were determined by quantification with ImageJ software 
of band density normalized to a tubulin loading control using several different 
exposures for each blot and at least three replicate sample preparations in each 
cell type. (OMM=outer mitochondrial membrane, MM= mitochondrial matrix, IM= 
inner membrane of mitochondria)   
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Fig 22: Steady state levels of representative mitochondrial proteins in cells 
depleted of SBDS relative to Scr controls. 
Upper Panel: Immunoblots of whole cell lysates from TF-1 cells transduced with 
lentiviral vectors targeting SBDS gene expression or scrambled controls.


















































Lower Panel: Quantification of band intensity using ImageJ software. Each bar 
represents the average of multiple band intensities over multiple experiments and 
exposures relative to a tubulin loading control. Error bars = S.E.M. 
(Cyt. C - Cytochrome C, SOD2 - superoxide dismutase 2, F.H.- Fumarate 
Hydratase) 
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Fig 23: Analysis of VDAC1 expression in TF-1 cells depleted of SBDS 
compared with scrambled controls.  
Upper panel:  Cell extracts were fractionated by SDS-PAGE, transferred to 
Nitrocellulose and were immunoblotted with antibodies raised to VDAC1, SBDS, 
and β-actin.  Lower panel: Quantification of band intensity from multiple blots 
show increase in VDAC1 expression with SBDS knockdown quantified using 
ImageJ software available from the NIH.  Graph represents the mean with S.D. 
used for error bars.  (*p<0.05 as determined by an unpaired Student’s t-test)
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Increased ROS production in cells depleted of SBDS
 Decreases in mitochondrial function are often associated with an 
increased production of reactive oxygen species. To assess ROS production in 
our model system we employed 2',7'-dichlorfluorescein-diacetate (DCFH-DA).  
This compound is rapidly cleaved by cellular esterases to the non-fluorescent 
compound DCFH.  DCFH, in turn, is oxidized to the highly fluorescent compound 
DCF in the presence of cellular peroxidases and ROS (Lebel and Bondy, 1990; 
Oyama et al., 1994; Rosenkranz et al., 1992; Trayner et al., 1995).   Figure 24A 
shows that cells depleted of SBDS generate ROS at a rate significantly greater 
than that of scrambled controls.  Furthermore, steady-state measurements 
indicated that cells depleted of SBDS had on average approximately double the 
amount of ROS compared to controls (Fig. 24B).  
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Fig 24: Analysis of ROS levels in TF-1 cells depleted of SBDS 
(A) Representative fluorescence emission with time after treatment with 20 µM 
DCFH-DA.  (B) Data were plotted as relative fluorescence units in either TF-1 
cells depleted of SBDS or scrambled controls.  Values represent an average of 
three independent experiments. Error bars represent S.D. (*p < 0.05  
** p< 0.01 *** p< 0.001 ****p< 0.0001, as determined by an unpaired student’s t-
test with earliest time point of specified variation labeled)
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Treatment with a reactive oxygen species scavenger in SDS models has 
been shown in prior works to reduce the amount of ROS created with SBDS 
knockdown samples (Ambekar et al., 2010).  To determine if the enhanced ROS 
production in cells depleted of SBDS was limiting growth, we asked whether the 
anti-oxidant N-acetyl-cysteine, (NAC), is capable of rescuing the growth deficit 
associated with loss of SBDS shown in Figure 16.  Figure 25 shows that the 
addition of NAC had very complex effects in our tissue culture system.  First and 
foremost, NAC appears to exhibit a dose dependent toxicity to scrambled control 
TF-1 cells.  As there are no published studies examining the effects of NAC in 
TF-1 cells, it is unclear whether this observation is peculiar to our model system 
or is a general characteristic of TF-1 cells.  In TF-1 cells depleted of SBDS this 
toxicity appears somewhat reduced, and at higher concentrations of NAC growth 
appears to be rescued (Fig. 25).  
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Fig. 25: Complex effects of NAC on growth and viability of TF-1 cell 
cultures. 
TF-1 cells transduced with shRNA targeting SBDS or a scrambled control 
sequence were treated with the concentrations of NAC shown on the x- axis. 
After 24 hours the samples were counted using trypan blue exclusion for cell 
viability.  Values on the y-axis present the percentage of cell growth during the 24 
hour immediately after treatment.  Percentages were calculated by the count of 
viable cells after treatment divided by the pre-treatment number of cells multiplied 
by 100. The numbers shown are the average of three independent experiments 
with error bars representing the standard deviation.   The red line represents the 
x-axis at  0, which represents an equal amount of cell growth and cell death in 
the 24 hour time frame.  
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Discussion
 We have developed a model of SDS that allows us to study aspects of 
disease pathophysiology in a human cell line of myeloid lineage.  TF-1 
erythroleukemic cells transduced with lentiviral vectors targeting SBDS gene 
expression were used in these experiments.  These cell lines showed less than 
30% of scrambled control levels of SBDS mRNA levels and nearly undetectable 
protein levels (Fig. 14).  The low levels of SBDS observed in our system are a 
reasonable approximation to the situation in SDS patients where trace levels of 
SBDS are expressed from hypomorphic alleles in this autosomal recessive 
disorder (Boocock et al., 2003).  
Our models system exhibited many of the hallmarks associated with 
reduced SBDS expression in a number of other systems.  SBDS is known to 
function in ribosome biogenesis.  In yeast models of SDS, SBDS is required for 
the release of the anti-association factor Tif6, the yeast ortholog of eIF6, from 
fully matured 60S subunits in the cytoplasm.  The continued presence of Tif6/
eIF6 on 60S subunits in the cytoplasm prevents their association with 40S 
subunits in forming 80S initiation complexes and so reduces the translational 
capacity of cells.  The lack of recycling of Tif6/eIF6 back to the nucleus also 
eventually leads to the nuclear accumulation of pre-60S subunits as Tif6/eIF6 is 
also required for late steps in the maturation of 60S subunits in the nucleus 
(Menne et al., 2007; Moore et al., 2010).  In our system the most apparent effect 
of the depletion of SBDS on the translational machinery is a reduction in 
polysomes consistent with a decrease in the number of functional ribosomes.  
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Further we found that this decrease in translational capacity correlated with an 
increased presence of eIF6 in the 60S subunit fraction.    
 Neutropenia is the most common blood lineage dysfunction seen in SDS 
with  disease severity often relapsing and remitting over time and can often 
include other BM lineages (Burroughs et al., 2009).  SDS predominantly affects 
cells of myleloid lineages which is why we turned to TF-1 cells in creating our 
cell-based model.  TF-1 cells are able to undergo partial myeloid or erythroid 
differentiation when grown in either GM-CSF or EPO, respectively (Miyake et al., 
2005).   Our experiments demonstrated that depletion of SBDS reduced 
differentiation along both myeloid and erythroid lineages (Fig. 19).  Other cell 
models have shown that SBDS is an important regulator of differentiation and 
proliferation of hematopoietic cells of both erythroid and granulocytic lineages, 
which is congruent with our findings and marrow phenotypes observed in SDS 
patients (Sen et al., 2011).   In addition to the failure to differentiate along 
erythroid and granulocytes lineages, the TF-1 cell model reported here also 
shows a delay in cell cycle progression associated with decreased SBDS 
expression.  
  A major focus of our efforts with the TF-1 cell model of SDS was to 
determine if decreased expression of SBDS would interfere with mitochondrial 
function.  These experiments were based, in part, on the observation that yeast 
cells depleted of Sdo1 were unable to grow on non-fermentable carbon sources.  
Another observation that directed us towards an assessment of mitochondrial 
function was a recent report indicating that mammalian cells depleted of SBDS 
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showed an increase in ROS production.  As mitochondria are a major source of 
ROS in many cells types and increases in ROS production is sensitive to mild 
uncoupling of the mitochondrial membrane potential it seemed reasonable to 
hypothesize that cells depleted of SBDS could have compromised mitochondrial 
function.   
 We employed two independent approaches to assess mitochondrial 
function in human TF-1 cells depleted of SBDS.  The first was to measure 
oxygen consumption while the second was to evaluate mitochondrial membrane 
potential.  The rates of basal and maximal oxygen consumption in SBDS 
knockdown cells were  reduced  relative to scrambled controls (Fig 20).  The 
effect on basal oxygen consumption appeared greater when comparing the 
slopes of oxygen consumption curves before and after CCCP addition. The ratio  
in SBDS depleted samples was increased approximately 18% relative to 
scrambled controls suggesting there were affects on both mitochondrial mass 
and function.  The finding that mitochondrial membrane potential also appeared 
lower in cells depleted of SBDS is consistent with an effect on mitochondrial 
function.     
The work outlined here is the first to describe mitochondrial dysfunction in 
cells depleted of SBDS.  Intriguingly however, these are not the first studies to 
link mitochondrial dysfunction to a bone marrow failure syndrome.  Pearson’s 
syndrome, which is caused by mutations in mitochondrial DNA, is characterized 
by anemia/pancytopenia and defective exocrine pancreas failure, reminiscent of 
the cardinal pathologies seen in SDS (Lee et al., 2007; Shimamura and Alter, 
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2010; Topaloglu et al., 2008; Williams et al., 2012).  Whether these two 
syndromes will converge to a common underlying pathological mechanism based 
on mitochondrial dysfunction remains to be seen.  
We have examined the steady-state levels of a number of mitochondrial 
proteins to obtain a better perspective on changes brought about on 
mitochondrial function in cells depleted of SBDS.  We have seen no consistent 
pattern of changes in expression of mitochondrial proteins involved in the 
organelle import machinery or in antioxidant defense enzymes in response to 
SBDS depletion.  Two proteins in each of these classes were examined with one 
increasing expression and the other decreasing expression in both cases.  One 
feature of this analysis which may be of note is the finding that proteins directly 
involved in energy metabolism, PDH, IDH3α, and cytochrome c are all decreased 
in cells depleted of SBDS.  A decrease in the activity of the TCA cycle, linked to 
reduced IDH3α activity, or reduced acetyl-CoA as a result of decreased activity of 
PDH, could have an impact on mitochondrial membrane potential as could lower 
amounts of cytochrome c.    
Compromised function of the electron transport chain could in principle 
lead to an increase in ROS generation such as that observed now in two different 
models of SDS and in multiple models of altered cellular metabolism in 
carcinogenesis (Ahn et al., 2008; Bell et al., 2011; Bell and Guarente, 2011; 
Choudhary et al., 2009; Finley et al., 2011; Haigis et al., 2012; Hanahan and 
Weinberg, 2011; Huang et al., 2010; Kim et al., 2010; Schumacker, 2006).  While 
at present this relationship is simply a correlation, it does represent a fruitful area 
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of investigation.  The finding that the antioxidant NAC rescues some of the 
growth characteristics of cells depleted of SBDS suggests that the increase in 
ROS production may be a contributing factors to SDS pathophysiology.  
Finally, similar to what was observed in yeast we see an increase in the 
amount of VDAC1 in cells depleted of SBDS.  Both increased and decreased 
expression of VDAC1 has been linked to apoptosis  and so it is possible that 
changes in VDAC levels could potentially contribute to enhanced cell death in 
cellular models of SDS.  
Changes in particular mitochondrial proteins, in addition to VDAC1, are 
reminiscent of other experiments performed in our lab and the works of others.  
Joseph Moore IV, formerly of the Ellis lab and in collaboration with researchers at 
Texas A & M, performed a drug screen for rescue of the growth deficit of SDO1 
yeast strains.  They discovered that the HDAC inhibitor TSA could lead to global 
changes in protein expression and acetylation that mimicked the wild-type 
samples as well as rescuing the growth deficit.  In other settings where global 
protein acetylation is affected by loss of a protein responsible for deacetylation, 
loss of SIRT3, a member of another HDAC family, in both mouse models and 
yeast strains, leads to changes in global protein acetylation (Ahn et al., 2008; 
Choudhary et al., 2009; Kim et al., 2010; Tao et al., 2010).   It is one of a class of 
acetylation regulating enzymes called sirtuins, and this particular one is the major 
mitochondrial form that functions as an NAD-dependent de-acetylase.   For 
example, the mitochondrial reactive oxygen species scavenger SOD2 is 
hyperacetylated and cannot perform its normal functions efficiently (Tao et al., 
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2010).  This prevents the mitochondria from dealing with normal concentrations 
of superoxide radicals while simultaneously in this system Hif1α, a hypoxia 
induced transcription factor, increases the expression of gene targets responsible 
for the so-called Warburg effect(Bell et al., 2011; Bell and Guarente, 2011; Finley 
et al., 2011). The Warburg effect is the mechanism by which cancerous cells 
preferentially metabolize glucose, even at the expense of generating large 
concentrations of reactive oxygen intermediates through inefficient oxidative 
respiration (Schumacker, 2006; Warburg, 1956). The acetylation status of 
multiple proteins, in addition to the changes in protein expression mediated by 
Hif1α, promote the reprogramming of cellular metabolism and the drive toward 
glycolysis as the sole energy producing pathway (Ahn et al., 2008; Choudhary et 
al., 2009; Finley et al., 2011; Haigis et al., 2012; Hanahan and Weinberg, 2011; 
Huang et al., 2010; Kim et al., 2010; Tao et al., 2010).  One downstream 
modification is to decrease expression of SOD2. Thus, overall ROS levels are 
increased by two mechanisms, both an increase in the production of ROS from 
the increased activity of the electron transport chain given the cell’s preference 
for metabolism of glucose, and a decrease in protein levels of SOD2 and the 
efficiency of super oxide radical scavenging of the individual SOD2 proteins due 
to hyper-acetylation (Ahn et al., 2008; Bell et al., 2011; Bell and Guarente, 2011; 
Finley et al., 2011; Haigis et al., 2012; Kim et al., 2010; Tao et al., 2010).  There 
are questions left to answer in the complex interplay between SBDS, ROS, and 
the function of the mitochondria in SDS pathophysiology. 
 122
Together, our findings point to mitochondria as a source of new 
physiologic functions for SBDS, which adds to its reported roles in ribosome 
synthesis, chemotaxis, and mitotic spindle assembly (Ambekar et al., 2010; 
Austin et al., 2008; Ball et al., 2009; Brina et al., 2011; Finch et al., 2011; 
Ganapathi et al., 2007; Leung et al., 2011; Nihrane et al., 2009; Orelio et al., 
2011; Orelio et al., 2009; Rawls et al., 2007; Sen et al., 2011; Smith et al., 1996; 
Watanabe et al., 2009; Wong et al., 2011; Yamaguchi et al., 2011; Yamaguchi et 
al., 2007).
 123
Conclusions and Future Directions
The complex role of SBDS in cellular metabolism and respiration is 
inevitably far more intricate than the scope of this dissertation work.  These 
studies were initiated to follow up on the observation that yeast lacking Sdo1, the 
Sbds ortholog, were unable to grow on non-fermentable carbon sources 
indicating a defect in mitochondrial function.  We used multiple approaches to 
study mitochondrial function in human cells depleted of SBDS, each of which 
were consistent with a role for SBDS in maintaining mitochondrial function.  
These studies present a new avenue of investigation into the pathophysiology of 
Shwachman Diamond syndrome.  Moreover, they also present new opportunities 
for therapeutic intervention. 
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 Research studies that did not easily fall under the same umbrella as the 
major works of my dissertation are found in the following sections.  These topics 
include verification of ribosome defects in an inducible mouse model of Rps19 
shRNA and  mouse embryonic stem cell (mES) models, all relating to Diamond 
Blackfan anemia (DBA). The mES models mimic haploinsufficiency for both 
Rps19 and Rpl5 in different cell lines, providing a tool for comparison of different 
DBA genes. 
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Supplemental Section 1: Mouse Embryonic Stem Cell Model
Introduction
 Macrocytic anemia of variable severity is the unifying feature of DBA 
diagnosis (Lipton et al., 1986).  Bone marrow biopsy is central in classifying this 
inherited bone marrow failure syndrome.  Classical DBA shows a red cell specific 
propensity for apoptosis in erythroid progenitors with an otherwise normocellular 
bone marrow (Miyake et al., 2008; Ohene-Abuakwa et al., 2005; Perdahl et al., 
1994; Tsai et al., 1989). Having a valid animal model to gain understanding of the 
molecular mechanisms that result in the vast array of features associated with a 
mutlifactoral disease such as DBA is of paramount importance.  In addition to 
potential advances in whole animal models, recapitulating central events in 
hematopoiesis in a tissue culture system could provide an alternative 
methodology to study DBA pathophysiology in the absence of a suitable animal 
model.   Stem cell cultures have been used to mimic differentiation of progenitors 
and study erythropoiesis defects in other contexts, but not in DBA (Choi, 1998; 
Keller, 2005)  To this end, mouse embryonic stem cells were used to mimic 
haploinsufficiency for known DBA genes.  These gene trap constructs were 
created by retroviral insertion within the genes for Rps19 or Rpl5 that causes a 
premature termination of the gene transcript in only one copy of the gene (Keller, 
2005) .  With appropriate culture conditions and appropriate cytokine stimulation 
they can be induced to differentiation into blood lineage specific colonies in the 
manner shown in Fig. S1.  
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Fig S1:  Embryonic stem cell culture recapitulates hematopoiesis in mouse 
models. 
Differentiation of mES models can be used to mimic the in vivo erythrocyte 
development with representative images of ES cell and embryoid bodies (EBs) 
shown in the inset pictures.  Adapted from previous works (Keller, 2005).  
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 Stem cells in this system can be grown in an undifferentiated state to 
represent the HSC multipotent progenitor or undergo primary differentiation in 
methylcellulose media to form embryoid bodies. The viscous nature of 
methylcellulose is necessary for the sensitive stem cell progenitors to receive 
appropriate structural interactions with the surrounding environment to 
differentiate.  On specific days of differentiation, as outlined in the in vitro time 
line of Fig. S1, the EBs can be harvested and induced to form primitive or 
definitive erythroid colonies. Primitive erythroid colonies express variants of 
hemoglobin specific to fetal development, such as Hbb-bh1. This can be thought 
of as analogous to the fetal hemoglobin chains produced during human 
embryogenesis (Hb-F = Hemoglobin Fetal).  Definitive erythropoiesis is 
responsible for the production of red cells in adult animals and can be modeled 
by harvesting EBs later in their development before inducing differentiation with 
SCF (Stem cell factor), IL-3, IL-6, and epo to form burst forming units of the 
erythroid lineage (BFU-Es). In mice adult hemoglobin is Hbb-b1.  
 The mES models represented here were described earlier in the materials 
and methods section, but will be briefly reviewed here. Two different cell lines 
heterozygous for Rps19 were used in an attempt to recapitulate the pathology of 
haploinsufficiency for Rps19.  The S17-10H1 line was created by genetrap 
insertion between exon 2 and 3 in the Rps19 gene of the Ak7 mouse parental 
line.  A “rescue” of this cell line was generated by electroporation of a plasmid 
expressing Rps19 from a cDNA insert and termed “ORF-S17.”  Because the 
electroporation necessitated antibiotic selection, an empty vector plasmid was 
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also electroportated into the S17 cell line and called “EMT-S17.” Both lines were 
screened for uptake of the plasmid using puromycin selection. Effectively the 
EMT-S17 should model the original gene trap line, with one copy of Rps19 
inactivated, and the ORF-S17 should serve as a control line. The second Rps19 
model of haploinsufficiency has a gene trap insertion between exons three and 
four of the E14 parental cell line to generate the YHC074 gene trap line. The 
Rpl5 model was created by gene trap insertion between exon three and four of 
the Rpl5 gene in the parental TBV cell line to generate the D050 mutant line (Fig 
3 and 4 of Chapter 3).  
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Results
 In order to establish the gene trap cell lines as useful models of DBA, 
reduced expression of the gene products that have been targeted must be 
established.  All three cell lines were found to contain the reporter gene mRNA by 
qRT-PCR as well as knockdown of the mRNA transcript for Rps19 or Rpl5 where 
appropriate (personal communication via Dr. Tracie Goldberg and Dr. Sharon 
Singh of the Feinstein Institute for Medical Research, data not shown).  The 
Rps19 mES cells provided the most consistent and reproducible protein 
knockdown (Fig. S2).  Our collaborators at the Feinstein Institute were able to 
show an initial protein knockdown in the Rpl5 samples (Fig. S3). 
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Fig S2:  Protein knockdown of Rps19 in mES cells evidenced by 
immunoblotting. 
Whole cell lysates were used for immunoblotting using antibodies raised against 
Rps19 and β-Actin.  (A) YHC (Rps19 gene trap) and corresponding E14 parental 
control blotted for Rps19 and β-Actin. Band density was quantified by ImageJ 
software and  showed an ~80% knockdown of Rps19 protein expression relative 
to the β-Actin loading control.  (B) ORF-S17 and EMT-S17 mES gene trap 
samples grown with or without antibiotic selection to maintain the gene trap 
construct.    The ORF-S17 is a corrected clone of the gene trap and therefore 
used as a control, while the EMT-S17 only has one functional copy of Rps19. 
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The blot was quantified using ImageJ and was determined to have approximately 
30% knockdown of Rps19 protein expression relative to β-Actin loading control.  
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Fig S3: Protein knockdown of Rpl5 in mES gene trap samples.  
D050 Rpl5 mutants and their corresponding YHC parental control mES whole 
cell lysates were Western blotted for Rpl5 and β-Actin expression by Dr. Tracie 
Goldberg.  
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In addition mRNA and protein knockdown, characteristic processing 
defects in the maturation of rRNA as outlined in Chapter three should also be 
present.  Total RNA was isolated from mES cells and used for Northern blotting 
as previously outlined (Flygare et al., 2007).   In both DBA patients and cell 
culture models with haploinsufficiency for Rps19, there is a delay in the 
processing of 18S rRNA that can be identified at the cleavage step of 21S pre-
rRNA into the more mature 18SE pre-rRNA when total RNA is Northern blotted 
using a probe called “18SE.”  This probe is complementary to the 3’ end of the 
18S rRNA and the 5’ end of ITS1.   This processing defect is evident as an 
increase in the ratio of the 21S precursor relative to 18SE.  Figure S4 shows a 
representative Northern blot of the YHC Rps19 mutant cell line and its parental 
control, E14.  The average ratio of 21S to 18SE in four separate experiments in 
represented in the bar graph next to the blot.  This increase in the 21S:18SE ratio 
represents an average 1.55 fold change when the mutant is normalized to the 
parental sample, which is on par with the inducible mouse model presented in 
supplemental section 2.  
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Fig S4: Mouse embryonic stem cells (mES) heterozygous for Rps19  
display processing defects in pre-rRNA expected for Rps19 
haploinsufficiency.
Representative Northern blot (left) and quantification of replicate data of total 
RNA harvested from mES cells with gene trap for Rps19 and parental controls.  
An increased ratio of 21S to 18SE pre-rRNA is evident.  This delay in the pre-
rRNA processing was reproducible and statistically significant. (Bar graph 
represents the mean, with S.D. used for error bars, n=4, *p<0.05. As determined 
by an unpaired Student’s t-test)
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 To determine if the gene trap cell lines affected the production of ribosomal 
subunits  we also analzyed polysome profiles from these cell lines.  Figures S5 
and S6 show representative polysome profiles from mES samples. 
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Fig. S5: mES samples with haploinsufficiency for Rpl5 show a decrease in 
polysome size. 
(A) A schematic representing changes in polysome profiles depending on which 
ribosomal subunit is affected.  Polysome profiling gives a general overview of the 
translational machinery in cells.  The number of ribosomes translating a given 
mRNA at any time is dependent on the rates of initiation, elongation, and 
termination as shown in the top example in portion (A). Changes in levels of the 
40S and 60S subunits typically affect initiation giving smaller polysomes.  The 
larger the number of ribosomes on a message the higher the initiation rate.  
When the 40S subunit becomes limiting, such as in models of Rps19 
haploinsufficiecy represented in the middle schematic, there are fewer ribosomes 
attached to a given mRNA, causing a left shift in polysomes and a relative 
excess of free 60S subunits.  This occurs because the 40S subunit must bind to 
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the mRNA first before a pre-initiation complex can prepared for subsequent 60S 
subunit binding. The bottom example, in which 60S subunits are limiting, as in 
Rpl5 haploinsufficiency, a 40S subunit may be attached to the mRNA, but has 
difficulty locating a 60S subunit capable of binding to it which leads to fewer 80S 
initiation complexes formed and reduced initiation rates.  
(B) This shows a representative polysome profile from mES samples with a gene 
trap targeting Rpl5.  The parental cell line absorbance tracing (YHC) is shown in 
black with the mutant (D050) absorbance tracing shown in red.  Though the 60S 
subunit peak does not seem to be as severely affected as in the Rps19  models 
to follow, a modest defect appears in the polysome region and a slight leftward 




Fig. S6: mES polysome profiles in Rps19 genetrap.
Two mES cell lines with gene traps targeting Rps19 were treated with 
cyclohexamide and harvested for polysome profiling.  (A) The parental E14 mES 
line generated the absorbance tracing shown in black and the mutant  YHC 
absorbance tracing was overlaid in red.  When normalized to the 40S subunit, 
there is an appreciable relative decrease in the 80S subunit. The 60S subunit 
appears to be proportionally increased, but this is to be expected in the setting of 
abortive ribosomal assembly of 40S subunits when Rps19 is in limiting quantities. 
(B) A representative absorbance tracing of the ORF-S17 mES gene trap with 
corrected Rps19 protein expression is shown in black and the EMT-S17, mutant 
mES cell line is overlaid in red.   The most appreciable defects in this system are 
 185
found in both the 80S subunit formation decrease and also as a trend toward 




 The protein knockdown of the ribosomal proteins targeted by the gene 
trap cell lines in addition to the ribosomal defects shown in polysome profiles, are 
suggestive of a specific subunit defect. At best, these data are far from concrete, 
but demonstration of ribosome synthesis deficiencies have never been as robust 
as those in human model systems.  In addition to the ribosomal biology findings 
presented in the results section, collaborators at the Feinstein Institute made 
several important findings not presented as data in this dissertation.  
 They have been able to demonstrate defects in embryoid body formation 
as well as the ability to generate hematopoietic type colonies in all three cell 
lines, but the Rpl5 line uniquely generated smaller individual embryoid bodies.  
Preliminary data has shown a decreased ability for definitive erythropoiesis in all 
three cell lines, but the YHC cell line was able to maintain the efficiency of 
primitive erythropoiesis.  There was also an increase in the p53 expression 
based on flow cytometry, but the initial experiments are not yet replicated.  All 
defects tested were rescued by either p53 inactivation or cDNA re-expression of 
the gene targeted in the gene trap.    Additionally, knockdown of Rpl11 
expression in addition to the original genetrap defects increased all measureable 
defects.  We hypothesize this is due to the role of Rpl11 in the MDM2-p53 
pathway in cooperation with 5S rRNA and Rpl5.  
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Conclusions and Future Directions 
  The mES model represented here is taking shape as a method to 
recapitulate and further investigate the molecular mechanisms leading to the 
block in maturation of erythroid precursors in DBA.  There are several studies 
represented here and in the works of our collaborators that need to be replicated 
and statistically analyzed. Once these findings are determined to be reproducible 
they can be used to test potential therapies.  It represents a model of 
haploinsufficiency that has been difficult to produce in whole animal models.  As 
a tissue culture method, it offers a high throughput method to screen multiple 
drugs, or other therapies, and generate a specific dose response to a positively 
screened compound.  Also, it has the specific advantage of analysis at the 
specific phases of hematopoietic differentiation of HSC that is the unifying feature 
of the constellation of features that make DBA a diagnostic and therapeutic 
challenge.  If the defect in maturation of pre-erythroid cells can be reversed in 
this model, the potential validity is greatly increased.  It certainly lends itself well 
to a pre-screening of potential therapies before the needless sacrifice of animals 
to potentially hazardous treatments.  
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Section 2: Inducible Rps19 Depletion Mouse Model
Introduction
 This section represents some data used in the manuscript, Jaako et al in 
Blood 2011 (Jaako et al., 2011), though all figures used were newly adapted for 
this dissertation. This section outlines the validation of a potential mouse model 
for DBA.  An inducible knockdown of the most common DBA gene, Rps19, was 
developed to circumvent several pitfalls of previous animal models. By allowing 
for normal expression of ribosomal protein genes during fetal development, the 
embryonic lethality shown with the homozygous deletion of Rps19 (Matsson et 
al., 2004) was avoided, and by adding one or two copies of an inducible shRNA 
to the genome of the animal theoretically creates an ability to express a broad 
range of Rps19 knockdown levels.   Thus, this animal model is uniquely poised to 
display phenotypic manifestations of Rps19 knockdown in contrast to the 
heterozygous knockout mouse that showed very few changes in any of the 
originally measured parameters (Matsson et al., 2004).  
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Results 
Embryonic fibroblasts (MEF) cells were harvested for growth in tissue 
culture as previously described (Jaako et al., 2011).   As outlined in the methods 
section, the samples contained one (genotypes B/+ and D/+) or two (genotype B/
B) copies of an inducible shRNA sequence targeting Rps19 mRNA labeled “B” or 
“D,” under control of a tet-on promoter located in the collagen A1 locus.
 MEF samples grown in culture in the presence of doxycycline were 
compared to untreated control cultures of the same genotype (labeled +/+).  Total 
RNA was harvested from these cultures and used for Northern blot analysis to 
detect processing defects in the production of pre rRNA.  Figure S7A details the 
portion of the pre-rRNA processing pathway examined using the “18SE” probe 
next to a representative Northern blot image.   Both shRNA sequences increased 
the ratio of the immature 21S precursor pre rRNA relative to the downstream 
cleavage product 18SE pre-rRNA to a statistically significant level (Fig S7C).  
Mice given doxycycline in their drinking water for two weeks were sacrificed and 
their livers used for the same Northern blot analysis produced similar delays in 
the processing of pre-rRNA (Fig S7B).  
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Fig S7: Pre-rRNA processing defects associate with inducible Rps19 
shRNA expressing mouse model.
(A) Representative Northern blot of control (+/+) or single copy B shRNA 
targeting Rps19 (B/+) MEF total RNA labeled with 18SE oligo on the left and the 
corresponding pre-rRNA species on the right.  (B) Fold change in the ratio of 
21S:18SE pre-rRNA species normalized to the ratio in the control MEF harvested 
after seven days of treatment with doxycycline (n=4, * p<0.05).  
(C) Fold changes in the ratio of 21S:18SE pre-rRNA species normalized to the 
ratio in the control. Total RNA from animals given doxycycline in their drinking 
water for fourteen days expressing B (B/+) or D (D/+) sequence shRNA to target 
Rps19 gene expression. 
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 MEF samples grown in culture, as well as liver and bone marrow samples 
harvested from animals treated with doxycycline for two weeks were used for 
polysome profiling.  Figure S8 shows representative absorbance tracings from 
MEF, liver, and bone marrow samples.  Peak intensity corresponds to the relative 
amount of polysomes in each peak.
 MEF samples (Fig S8A) show a decrease in 40S and 80S subunits similar 
to profiles in bone marrow samples (Fig. S8C).  Liver samples of the B/+ 
genotype show a relative increase in the free 60S pool as well as defects in 80S 
formation (Fig S8B).  Liver samples of the D/+ genotype show a more 
pronounced 40S subunit defect as well as an 80S biogenesis decrease and a 
slight decrease in the absorbance of the polysome region (Fig S8D).  
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Fig S8: Polysome profiles of different cells and tissues from an inducible 
Rps19 shRNA mouse model. 
(A) MEF control and (B/+)   (B) Liver control and (B/+) (C) Bone marrow control 
and (B/+) and (D) Liver control and (D/+) representative absorbance tracings of 
cells harvested in cycloheximide and separated by size by ultracentrifugation on 
sucrose gradients.  
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 Printed absorbance tracings were trimmed at the baseline of each peak 
and the weight of the different peaks measured.  The absorbance peak can be 
thought of as an integral such that the area under the curve (weight) is 
proportional to the number of polysomes in that peak.  Liver polysome profile 
samples provided the most robust examples of small subunit deficiency in 
comparison to other tissue types sampled in these experiments, and peaks were 
weighed using this method.  Peak weight is shown as a percentage of the 40S 
subunit weight normalized to the 40S subunit in Fig S9.  
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Fig S9:  Peak weights of liver rRNA species separated on sucrose gradients 
and identified by polysome profiling. 
Ribosomal RNA species were identified in absorbance tracings, and peaks cut 
out individually from the tracing and weighed. The bar graph represents each 
peak as a percentage of total profile weight normalized to the 40S subunit (n=6, 
*p<0.05 as determined by an unpaired Student’s t-test)
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Discussion 
 Multiple publications have shown a delay in the processing of pre-rRNA 
from the polycistronic 45S precursor that generates the mature 18S, 5.8S, and 
28S rRNA species in both patient samples and animal models (Flygare et al., 
2007; Jaako et al., 2011; Robledo et al., 2008).  This model showed similar 
increases in the ratio of 21S: 18SE pre-rRNA in both MEF (Fig. S7A and S7B) 
and liver (Fig. S7C) samples further validating this ratio as a method for 
measuring functional consequences of Rps19 deficiency.  
 Polysome profile analyses were similarly supportive of a specific small 
subunit defect (Fig. S7).  The top left panel shows a representative diagram of 
MEF samples normalized to the 60S subunit absorbance peak to highlight a 
corresponding decrease in the absorbance maximum for 40S subunits as well as 
80S subunits, which is what would be predicted with a limiting quantity of 40S 
subunits.  This pattern was recapitulated in the liver samples with one inducible 
copy of the D shRNA shown in the bottom right panel.  Normalizing the liver 
samples with one copy of the B shRNA sequence to the 40S subunit also 
highlights a relative increase in the 60S subunit and decrease in the 80S subunit 
and polysome region shown in the top right panel.  At the time of submission of 
this dissertation, I am unaware of any other work that has shown polysome 
profiles generated from bone marrow samples.  The bottom left panel shows near 
absence of the 40S subunit as well as a decrease in the 80S peak absorbance. 
This data is less than ideal, but given the bone marrow failure of the animals 
depleted of Rps19, the starting material for this experiment was of limiting 
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quantities.  In liver samples each peak weight as a percentage of the total profile 
weight was graphed in Fig S8.  The shRNA sequence “D” was shown to have a 
greater effect on Rps19 gene expression (data not shown) and a statistically 
significant decrease in 40S subunit weight.  The 80S subunits of each of the 
Rps19 knockdown liver sample genotypes were shown to decrease, further 
supporting the functional lack of 40S subunits due to a decrease in Rps19.  
 Though data was not shown in the manuscript, the mouse model central 
to these studies recapitulated many of the hematopoietic defects pathognomonic 
of DBA in addition to the ribosomal defects outlined above.  These animals 
exhibit a macrocytic anemia, with additional defects in other blood lineages, 
which is not uncommon in the heterogeneous presentation of DBA (Farrar and 
Dahl, 2011).  These animals also display symptoms of bone marrow failure over 
time based on competitive transplantation assay, which is a hallmark of DBA 
pathophysiology.  The phenotype could be rescued by ectopic expression of 
Rps19 or loss of p53, cementing the specificity of the model (Jaako et al., 2011).  
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Conclusions and Future Directions 
 The molecular signatures highlighted by this work were previously 
published (Jaako et al., 2011). Without careful validation of the molecular 
pathophysiology characteristic of DBA, the specificity of an animal model is in 
question. The pre-rRNA processing and polysome profile defects link the bone 
marrow failure shown in the animal model to specific defects in Rps19. Now that 
this model has been validated, it has enormous potential in drug discovery and 
design, as well as more detailed inspection of the diverse biological pathways 




CGH- comparative genomic hybridization
DBA- Diamond Blackfan Anemia 
DC- Dyskeratosis Congenita 
DMEM- dublbecco’s modified eagle media 




FBS – fetal bovine serum 
FA- Fanconi Anemia 
FFME - formaldehyde, formamide,MOPS, ethidium
FISH – flow in-situ hybridization
GMCSF- granulocyte macrophage colony stimulating factor 
HRP- horse radish peroxidase
IBMFS- inherited bone marrow failure syndrome 
IMM- inner mitochondrial membrane 
IMS- intermembrane space 
ITS- internal transcribed sequence 
IDH- isocitrate dehydrogenase
LTR- long terminal repeat 
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MM- mitochondrial matrix
MEF- mouse embryonic fibroblasts 
mES- mouse embryonic stem cells 
mLIF- mouse leukemia inhibitory factor 
MMRRC- mutant mouse regional resource center
mRNA – messenger RNA 
MTG – monotioglycerol 
OMM- outer mitochondrial membrane 
ORF- open reading frame 
P/S- penicillin and streptomycin solution 
PDH- pyruvate dehydrogenase
RNA- ribonucleic acid 
ROS- reactive oxygen species 
RPL- ribosomal protein of the large subunit
RPS- ribosomal protein of the small subunit
rRNA- ribosomal RNA
SA- splice acceptor 
SCN-  severe congenital neutropenia 
SD- splice donor 
SDS- Shwachman Diamond Syndrome 
SnoRNP- small nucleolar ribonuclear protein 
SOD2- super oxide dismutase 2 (mitochondrial) 
TOMM- transfer channel of the outer mitochondrial membrane
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tRNA- transfer RNA 
TSA- trichostatin A
VDAC- voltage dependent anion channel 
Gene Abbreviations 
eIF6- eukaryotic initiation factor 6
RPS19 (Rps19)- small ribosomal subunit protein 19
RPL5 (Rpl5)- large ribosomal subunit protein 5
RPL11 (Rpl11)- large ribosomal subunit protein 11
SBDS – shwachman bodian diamond syndrome protein
SIRT3- NAD(+) dependent deacetylase sirtuin 3, mitochondrial 
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